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Lung produced surfactant protein D (SP-D) is essential for both homeostasis and as an 
innate immune opsonin. In the project presented here, we aimed to translate data 
recently published by our group, which demonstrated that SP-D contributes to 
protection against murine parasitic nematode infections, to human work. In the first part 
of this study, we determined whether individuals exposed to helminths have altered 
serum SP-D in comparison to unexposed individuals, through analysis (ELISA and 
Western Blot) of bio banked samples in 2 clinical cohorts from South Africa. Secondly, 
we aimed to identify if SP-D influences the magnitude of anti-nematode responses in 
human immune cells (type 2 innate lymphoid cells, monocytes and macrophages) 
through in vitro cell work and flow cytometry. Our findings indicated an association 
between serum SP-D and exposure to helminths that have a lung migration stage as part 
of their life cycle (Ascaris spp and Toxocara spp). Furthermore, in vitro analysis 
demonstrated that human immune cells primed with SP-D might have an altered 
response to helminth antigen. These findings point toward the need for further 
investigation into the novel role of SP-D in the control of human helminth infections in 








In this study we use human serum samples to assess if there is an association between 
surfactant protein D (SP-D) and helminth infections in order to determine whether it 
could be used as a novel anti-helminthic treatment. Immunity is often modified with 
repeated exposure to various pathogens and in many instances, this leads to immune 
regulation, which allows commensal micro-organisms to avoid destruction by host 
immunity. This also appears to be the case for some helminth infections; long-lived 
infections are associated with potent parasite induced regulatory responses. Recent pre-
clinical studies from our laboratory have linked the immunity and modulation of 
helminth infections with SP-D, a pulmonary collectin that interacts with mucosal 
immune effectors, most notably in the lung. SP-D is well understood as being able to 
both opsonize certain pathogens or to maintain tissue homeostasis depending on the 
immune environment. The SP-D induced modulation of helminth infection identified 
by the aforementioned study is a previously undescribed mechanism for pulmonary 
parasite control and showed raised SP-D levels enhances lung homeostasis and protects 
from immune pathology. In this study we explore the prospect of SP-D as a novel 
clinical treatment for soil transmitted helminth infections. This project focuses on 
determining whether an association between SP-D and immune markers of helminth 
infection (specific antibody isotypes) exists and what the exact mechanistic role of 
certain immune effector cells is and their potential interaction with SP-D, not only in 






1.1 The immune system 
Vertebrates live under the constant threat of invasion by harmful microorganisms and 
have evolved a system of immune defence that protects and eliminates pathogens from 
the body. Aside from the nervous system, it is the most complex system in the human 
body. Made up of different components variant in complexity, it functions in a few 
significant ways; pathogen neutralization, recognition of harmful substances, and 
autoimmunity towards the body's cells that change due to illness (i.e. cancers) [1].  
 
The mammalian immune system comprises of two main branches: innate and 
acquired/adaptive immunity. Innate immunity is our first line of host defence and is 
mediated by phagocytes including macrophages and dendritic cells. 
Acquired/adaptive immunity is involved in the elimination of pathogens at a later 
stage of infections and is responsible for immunological memory [1]. Immune function 
is highly dependent on how these haematopoietic cells of the innate and adaptive arms 
of immunity interact in their microenvironments with non-haematopoietic stromal 
cells. Stromal cells comprise of a range of tissue forming cells (epithelial, endothelial, 
fibroblasts, nerve, etc.) that create the architecture and molecular cues for 
haematopoietic cell-cell interactions determining growth, differentiation and survival. 
In other words, the stromal network organization imposes order on innate and adaptive 
immunity driving efficient responses to pathogens [2].  
 
In this body of work, we examine how our immune system, through the crosstalk of 
innate and adaptive arms interacts with parasitic nematode infections. To understand 
this complex interaction, we will first introduce the fundamental aspects of immunity 
and cellular crosstalk. 
1.1.1 Innate immunity  
The innate arm of immunity refers to non-specific host defences that are activated 
within hours of pathogen entry into the body. Discrimination between self and various 
pathogens happens through a limited number of pattern-recognition receptors (PRRs) 
such as toll-like receptors (TLRs) and mannose receptors; that is a type of C-type lectin 
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receptor, which recognizes conserved pathogen-associated molecular patterns 
(PAMPs)	[3]. Recognition via PRRs leads to inflammatory pathway activation through 
both haematopoietic and non-haematopoietic cells of the innate arm. This, in turn, leads 
to the secretion of both cytokines (messenger molecules) and more specialized 
chemokines (a type of cytokine that directs specific cells to the site of the immune 
response). Innate immunity has various arms of functionality; physical barriers (skin, 
gastrointestinal tract, respiratory tract, cilia, and other body hair), defence mechanisms 
(secretions such as mucous, bile, gastric acid, saliva, tears, and sweat), and generalized 
immune responses (inflammation, complement, and non-specific cellular responses). 
The strength of innate immunity is in its non-specific short start-up phase in response 
to pathogens. This broad effect means its non-specificity limits its capabilities. Innate 
immunity's complex nature is woven into how humans have evolved over millennia. 
Here we broke down its functionality based on the major immune cell types at play:  
 
Macrophages are large agranulocytes phagocytic cells found in the tissues that 
congregate at the site of infection. Depending on the environmental stimuli 
macrophages fall into two broad activation states; Classically activated macrophages 
are associated with Th1 responses which primarily engulf and destroy intracellular 
bacteria and viruses dependent upon inducible nitric oxide synthesis (iNOS) [4]. 
Alternatively, activated macrophages (AAMs) are rapidly recruited to the sites of 
helminth infection during Th2 immune response [5-7] triggered by IL-4, IL-13 and IL-
10 [4, 8]. Their primary functions during helminth infection involve the down-
regulation of Th1 response through IL-10 [9] [7] and wound healing by clearance of 
debris, growth and angiogenic factor release [10] which when combined provides a 
critical defence against invasive infections.  
 
Monocytes are stored in the spleen and circulate throughout the blood. These large 
leukocytes function to replenish resident macrophages under normal homeostatic 
conditions [11] as well as acting as responders to inflammatory signals and migrating 
to infection sites to differentiate into both macrophages and dendritic cells [11]. 
Migration is initiated by the inflammatory milieu and pattern-recognition receptor 
stimulation. Monocytes have emerged as facilitators of divergent immune functions 
during infectious disease with Turner et al. [12] suggesting both pro-inflammatory and 
anti-inflammatory states for the monocyte, not unlike macrophage classification.  
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Dendritic cells are antigen-presenting cells that play a crucial role in exposing antigen 
to T-cells that initiate immune the response. They are a link between innate and 
adaptive arms, promoting immunity to foreign antigen or tolerance to self-antigens 
[13]. They are present in tissues in contact with the external environment like 
epithelium, mucosa, lungs, gastrointestinal tract etc. They induce particular phenotypes 
in T-cells: Th1, Th17 and Treg – this is well established, but their role in inducing Th2 
phenotypes is unclear [14].  
 
Neutrophils are spherical granulocytes, phagocytic in nature, that are attracted to 
infected areas via chemotaxis in the bloodstream. The granulocyte contains an array of 
vasoactive mediators such as histamine, which establishes its role during fungal and 
extracellular bacterial infections not only through the production of pro-inflammatory 
cytokines but also through phagocytosis, reactive oxygen and nitrogen species 
(ROS/RNS) and neutrophil extracellular trap (NET) formation [15]. Recently, there has 
been a shift in studies focusing on more non-traditional and detrimental positions for 
neutrophils during disease, specifically inflammatory conditions that range from 
seasonal allergies to diabetes, viral infections and effects during cancer [16] 
 
Eosinophils are granulocytes containing a bi-lobed nucleus and large cytoplasmic 
granules. Expressing a broad array of ligand receptors that play roles in cell growth, 
chemotaxis, adhesion and degranulation the eosinophil activates complement via both 
classical and alternative pathways, synthesizes, stores and secretes cytokines, 
chemokines and growth factors. They stimulate T-cells via antigen presentation and 
promote humoral responses with B-cell interactions. Their presence amongst 
dead/dying parasites has proven them to be critical in defence against helminth 
infection as an end-effector cell. Eosinophils contain specific granule proteins that have 
potent cytotoxic effects that not only damage parasitic pathogens but in the process, the 
surrounding host tissue [17]. The granule proteins play a role in defence mechanisms 
not only against helminth infections but also viral and bacterial infections. The 
interactions of eosinophils with parasites and other pathogens are now recognized to be 
much more complex than previously thought [17]. 
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Mast cells are granulocytes, widely distributed throughout vascularised tissues 
(particularly skin, airways and gastrointestinal tract), containing large amounts of 
histamine and heparin [18, 19]. Along with dendritic cells, they are on the frontline of 
interaction with environmental antigens, toxins and invading pathogens. Mast cells 
express a high-affinity receptor for IgE, which makes them critical effector cells in IgE-
associated allergic disorders and parasitic infection responses [20]. Mast cell activation 
is very microenvironment and signal dependant. They play a prominent role in driving 
pathology associated with allergic disease and anaphylaxis but can also contribute to 
host defence by enhancing resistance to pathogens. In certain circumstances, mast cells 
can also limit inflammation and tissue injury by promoting host resistance [21], limiting 
pathology during some immune responses to environmental antigens [22], and act 
almost like adjuvants in developing protection against pathogens. This suggests that 
mast cells play a critical bridging role between innate and acquired immunity where, 
microenvironment dependant, they function on both sides of inflammatory homeostasis 
that can either promote health or contribute to disease.  
 
Basophils are closely related to mast cells, being a granulated cell containing histamine 
and heparin expressing high-affinity IgE receptor [23]. Basophils develop from a 
different haematopoetic lineage and leave the bone marrow already matured. They are 
the least abundant of all granulocytes and poorly understood due to the low abundance, 
short life span and lack of specific surface markers [23]. What is known is that they are 
critically involved in the development of T helper type 2 immunity both during 
infection with helminth and allergic responses.  
  
The complement system is part of the innate arm of immunity, comprising of a group 
of over 30 proteins and fragments that circulate throughout blood and tissue fluids. 
These molecules function through the stimulation of phagocytes which clear foreign 
and or damaged material, promote inflammation (enhancing immune cell recruitment) 
and attack cell membranes [24]. In response to the recognition of molecular 
components of a pathogen, they become activated in enzymatic cascade via three 
distinct pathways. Each pathway causes activation of C3 that is cleaved to C3a, which 
promotes inflammation, and C3b, which acts as an opsonin, binding to pathogen 
surfaces aiding in phagocytosis. Activated C3 also triggers lytic pathway damaged 
cellular membranes. C5a is also produced through the enzymatic cascade and attracts 
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macrophages, neutrophils and mast cells [24]. Classical pathway activation is a highly 
specific response, requiring antigen-antibody complexes for activation. In contrast, the 
alternative pathway is a non-specific response, where C3 hydrolysis is activated by 
allergens, pathogens or damaged cells. The mannose-binding lectin pathway is also 
non-specific and can be activated by spontaneous hydrolysis or antigens without 
antibodies present [24].  
 
Type 2 innate lymphoid cells (ILC2s), are a recently identified set of mononuclear 
hematopoietic cells with lymphoid morphology but distinguished from classification as 
a T or B cell due to absence of somatically rearranged antigen-specific receptors. They 
lie at the cusp of innate and adaptive immunity, falling within the innate arm of 
immunity but understood to provide critical linkage to adaptive defence cells such as 
dendritic cells and T-cells [25]. ILC2s are activated through extracellular parasites and 
endothelial damage responding by the release type-2 cytokines IL-13, IL-5, IL-9 under 
the transcriptional control of GATA3 and RORα [26]. The majority of ILC2 effector 
function comes from a considerable release of IL-13, which leads to the initial name 
given to the population, the Nuocyte – nu is Latin for "13" [25].   
1.1.2 Adaptive immunity  
The adaptive arm of immunity refers to pathogen-specific (antigen-specific) immune 
responses. In comparison to innate immunity, adaptive immunity has added layers of 
complexity whereby mounting an immune response can only occur once the antigen 
has gone through identification, processing and recognition. When recognition is 
complete, an army of immune cells is released, mounting a response to that specific 
antigen. The adaptive arm also provides a memory response, which allows for fast 
recognition of future infections by the same pathogens. The central cells of the adaptive 
immune system are T and B-lymphocytes. They are both derived from the same lineage 
of pluripotent haematopoetic stem cells but upon activation distinguish into 2 cell types 
with different functionality.  
T-cells play a central role in cell-mediated immunity. Maturation occurs in the thymus 
where they develop their unique T-cell receptor, which is responsible for low-affinity 
recognition of antigens bound to major histocompatibility complex (MHC molecules). 
They are split into effector (helper and cytotoxic subsets) and memory populations [27] 
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Based on their expression of CD3 combined with either CD4 or CD8. Effector 
populations respond immediately to stimuli, whereas memory cells are long-lived and 
target future infections. Helper T  cells (CD4+ T-cells), as the name suggests, assist 
other immune cells, for example, B-cells (maturation into plasma and memory cells) 
and activation of both cytotoxic T cells and macrophages [27]. Their activation comes 
from being presented antigen by MHC class II to molecules on APCs, they then 
differentiate to a particular subtype of helper cell that secretes specific cytokine 
profiles. CD4+ T-cells are subdivided into Th1 (promotes inflammation), Th2 (helps 
B-cells), Th9 (pathogen immunity and allergic responses), Th17 (promotes 
inflammation) and Treg (regulates immunosuppressive responses) groups. 
On the other hand, cytotoxic T cells (CD8+ T-cells), specifically destroy virus-infected 
cells and tumour cells. They bind to MHC class I molecules which are present on all 
cells containing a nucleus. They can also be inactivated to a dormant state that prevents 
reaction to self-antigen and ultimately autoimmune disease [28]. T-cells are antigen 
naïve until they are presented with their linked antigen (through MHC molecule on the 
surface of APC) that then allows them to differentiate and expand into memory and 
effector cells. Memory T-cells develop as long-lived cells that quickly expand on re-
exposure to linked antigen [28].  
B-cells and antibodies function on the humoral arm of immunity. The B-cells primary 
function involves binding to an antigen and receiving activation in either a T cell 
(antigen linked) dependant manner or independent manner. Stimulation leads to 
differentiation into a plasma cell that secretes a large amount of antibody [29]. B-cells 
also present antigen and secrete cytokines [30]. Antibodies can occur in two forms; 
soluble form that is secreted from the cell circulating in blood, and membrane form that 
attaches to the surface of B-cell becoming a receptor (BCR). The activation of the BCR 
determines the fate of the B-cell as plasma cells (antibody factories) or memory B-cells. 
Antibody genes can also reorder that changes the heavy chain fragment, creating a new 
isotype of the same antibody; this process is known as class switching. It is critical to 
allow a single antibody the ability to be expressed in different parts of the immune 
system. There are several other antibody classes IgA, IgD, IgE, IgG and IgM. The 
subclasses are characterized by biological properties, location of function and ability to 
bind to different antigens [31].  
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1.1.3 The other arms  
Non-haematopoetic stromal cells. Immunity does not just arise from its cellular 
components and their functions but also the microenvironments in which they exist. 
This microenvironment is determined by interactions between haematopoetic cells 
(immune cells) and non-haematopoetic stromal cells; which consists of a group of tissue 
forming cells (fibroblasts, endothelial, epithelial, nerve cells etc.), which are 
collectively known as the immune stroma [32, 33]. This environment makes up a 
landscape governing haematopoetic cell growth, survival, functionality and 
positioning; a level of organization enforces order upon innate and adaptive immune 
cells [33].  
1.2 Helminth infections 
1.2.1 Impact of helminth infections, lifecycles, symptoms and treatment  
Helminth is a general term meaning parasitic worm. These are eukaryotic invertebrates 
characterized by elongated, flat or round bodies. This body of work focussed on 
Nematodes (roundworms) with 3 major human species, two of which mature in humans 
and one which does not. 
	
Figure 1.1: Medically relevant helminths. Common medically relevant human helminth infections and 
their associated global prevalence separated by phyla—Diagram is sourced from Clinical Immunology 
(5th edition) [24]. 
Worldwide a large proportion of the human population (1.5 billion/20%) [34] is 
infected with one or multiple soil-transmitted helminths (STHs) (see figure 1.2); these 
are parasitic worms that are transmitted through contaminated soil [35]. There are 3 
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significant subgroups of STHs that account for the immense burden of disease; 
roundworm (Ascaris) (807-1,121 million), hookworm (576-740 million) and 
whipworm (604-795 million). Figure 1.2 (world map) shows that these parasites are 
most prevalent in tropical and sub-tropical regions of developing countries. The reason 
for this is 2-fold; firstly the warm and moist climate is favourable for growth and 
survival. Secondly, in developing nations, there is limited access to clean water, 
sanitation and particularly efficient sewage disposal (STH life cycles rely heavily on 
human exposure to sewage) [36] [37].  
	
Figure 1.2: Global distribution of soil-transmitted helminths. Data from 2010 global atlas of helminth 
infection sourced to show global estimates of Ascaris lumbricoides, Trichuris trichuria, Necator 
americanus, and Ancylostoma duodenale. Trends in parasitology, Jan 2016 [34]. 
Helminth life cycle. Soil-transmitted helminth infections colonize in the intestine (area 
depends on species), with their eggs being passed through the faeces of an infected 
individual. Both Ascaris and hookworm eggs mature in soil and become infective [38]. 
In places with poor sewage management, human-faeces contact is increased, leaving 
the eggs with a higher chance of being transferred (consumed orally) to another 
individual through direct contact, water supply contamination, fertilizer 
mismanagement or consumption of unwashed food [38]. Hookworm eggs are slightly 
different and do not mature to become infective in soil, instead, they hatch in soil 
releasing larvae that mature to a form which penetrates human skin through direct 
contact, for example, walking barefoot over the contaminated area.  
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In terms of sub-Saharan Africa, The research centred around two STH's that have the 
most considerable impact for the burden of disease: Ascaris lumbricoides (Figure 1.3 
A) and Trichuris trichuria (Figure 1.3 B) [39]. For mechanistic comparison, a helminth 
infection that turns humans into a dead-end host was included, with a slightly more 
variable life cycle, Toxocara spp (Figure 1.3 C).  
 
	
Figure 1.3: Life cycles of helminths. (A) Ascaris, (B) Trichuris and (C) Toxocara. Lifecycle diagrams 
courtesy of Centers for Disease Control [24].   
Symptoms. The importance of soil-transmitted helminth infections may not lie in the 
sheer volume of people infected but in the demographics of those affected. According 
to the WHO, roughly 267 million preschool-age children and 568 million school-age 
children live in areas where these parasites are frequently transmitted and require 






infection, with the individual being totally asymptomatic, to heavy infections causing 
a range of health problems. Although outward helminth morbidity is rare, immune 
impairment generated from infections affects bacterial and viral clearance, such that the 
WHO has indicated that eradication of helminthic infections may be essential for 
successful vaccination against life-threatening diseases like human immunodeficiency 
virus (HIV) and tuberculosis (TB) [40]. Morbidity and symptoms are centred around 
the gut due to the STH lifecycle. Infections with more considerable morbidity (more 
worms) will cause intestinal issues such as diarrhoea and abdominal pain, malnutrition, 
malaise and weakness, eventually causing impairments in development and growth. 
The helminth infection has various mechanisms by which it impairs growth; worms 
feeding directly on host tissues leading to loss of iron and protein, intestinal 
malabsorption (including roundworm competition for vitamin A [41]), hookworms 
cause chronic intestinal blood loss leading to anaemia, and the loss of appetite that 
usually accompanies any GIT illness and therefore reduction in nutritional intake. In 
the case of Ascaris, larval migration, through direct mechanical force, can cause 
substantial pulmonary damage with type 2 pathology resembling allergic airway 
disease (Figure 1.3). As previously mentioned helminth infections generally centre 
around more impoverished communities of the tropics and subtropics, with the struggle 
of poor socioeconomic circumstances, the added burden of a chronic and debilitating, 
but curable, disease inflicts unnecessary burden. This perpetuates a brutal cycle of poor 
health, whereby STHs result from poor socioeconomic conditions and contribute to 
further poor health through there long term effect on public health.  
 
Treatment. The current public health control strategies in place for helminth infection 
control include chemotherapeutics and vector control strategies. The chemotherapy 
uses medications such as lbendazole, mebendazole, levamisole, and pyrantel pamoate, 
all of which target the mature worm through metabolic starvation or paralysis [42]. 
Vector control is, at best, an adjunct strategy with limited efficacy [37]. Both strategies 
have the same social, logistical and economic issues with long treatment lengths, 
remote areas of distribution and the development of some drug resistance [37]. In 
livestock, the development of resistance to these drugs is widespread [34]. 
Consequently, a need exists for novel anti-helminthic treatments with a new mechanism 
of action to put an end to the unnecessary disease that is curable and help prevent the 
onset of parasitic drug resistance in humans. 
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1.2.2 The host-parasite interaction 
Helminths are complex eukaryotic organisms that are characterized by their ability to 
maintain chronic infections in a host. The host-parasite interaction is a complicated 
physiological response for several reasons: (1) Lifecycles are characteristically 
complex resulting in the host being exposed to unique antigen repertoires throughout 
an infection. For example, in lymphatic filariasis, the host is exposed to larvae at the 
skin, lymph nodes and lymphatics; adult worms in lymph nodes; and microfilariae in 
peripheral circulation [43]. (2) Unique tissue tropism in each area of infection 
(cutaneous, pulmonary, and intestinal) and migration patterns of the helminths means 
that the immune-stromal interaction that is activated can be highly variant. For 
example, an Ascaris infection in the lung must mediate the inflammatory response 
because gaseous exchange is vital for host survival. (3) This is further complicated by 
the fact that an infected host could be exposed to multiple stages of the parasite 
concurrently if they remain in an endemic area. The following immune response will 
not only be a reaction to the new parasite but also have the imprint of the current or 
previous infection on immune response [42] [44].  
 
The longevity of helminth infections may be at least partially attributable to the ability 
of the parasite to alter regulatory immune responses within its host. Host death before 
parasitic lifecycle is complete would be biologically redundant. This has led to an 
almost unified host-parasite interface creating carriers that are relatively asymptomatic 
reservoirs for transmission [45]. This alteration of the immune response can also 
fundamentally change the way our bodies respond to other immune stimuli [45]. Over 
time parasite infection down-regulates the type 2 immune response [46], towards both 
helminth antigen and non-related antigens [44], explaining the success of parasite 
invasion in the tightly regulated areas such as the mucosa. The immunoregulatory effect 
of these bystander responses also critically affect immune reactions to viruses and 
bacteria [47], causing a critical downregulation of cellular immunity that is required to 
prevent intracellular infection, such as HIV and TB [47]. 
 
1.2.3 Classical host immune response 
Despite the wide variation, there remains a distinct type 2 skewing of the immune 
system [48] [49]. This is depicted by release, activation and expansion of Th2 cells 
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producing several key cytokines; IL-4, IL-5, IL-9, IL-10, IL-13 and the activation of 
plasma cells secreting immune isotypes IgE, IgG1 and IgG4 [50]. This, in turn, leads 
to the expansion in cell populations of eosinophils, mast cells, type 2 innate lymphoid 
cells and alternatively activated macrophages. Type 2 cytokine production mediated 
correctly triggers eosinophilia, mast cell activation, long term immunoglobulin release 
(IgG1, IgG4 and IgE), mucus secretion, goblet cell hyperplasia and fibrosis, which act 
together to expel helminths (Figure 1.4) [44]. However, mediated incorrectly, the type 
2 cytokines initiate pathology associated with excessive inflammation and fibrosis 
characteristic in allergic responses, including asthma [44]. Understanding this interplay 
of cellular effectors (Figure 1.4) generated by a helminth infection becomes critical 
when searching for novel means by which helminth infections can be combatted [51]. 
Whilst the predominant response is Th2 in nature, there is increasing recognition for a 
regulatory component of immune response involving a repertoire of regulatory cells 
and cytokines. 
	
Figure 1.4: Overview of a human immune response to helminth invasion. The human immune 
response with (1) acute and (2) chronic reaction to helminth invasion. Acute reaction causes epithelial 
damage, releasing IL-25, IL-33 and TSLP triggering downstream activation of ILC2s and dendritic cells. 
ILC2s are fast responders, releasing a large amount of IL-13 and activating eosinophils, slower to 
respond are dendritic cells that prime Th2 cell activation. This activation primes B-cells to produce both 
helminth specific and non-specific antibodies (IgE and IgG1). Both ILC2, T cells and Eosinophils 
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polarise macrophages to M2 phenotype. This M2 phenotype leads to modification of Th2 cells and 
chronic response of the human immune system. The chronic response becomes regulatory through the 
activation of Tregs and the inhibition of Th1 cell. B-cells also isotype switch leading to release of IgG4. 
Bystander effects include inhibition of helminth specific response, Th1 inhibition, vaccine efficacy 
reduction, dampening of allergic response and inhibition of metabolic disorders. Diagram created by Zoe 
Baker.  
The initiation, progression and culmination of the immune response to helminths 
involves an essential set of innate and adaptive cellular interactions with (1) 
epithelial/stromal cells, (2) innate lymphoid cells (ILCs), (3) dendritic cells (DCs), 
macrophages and monocytes; (4) T cells; (5) B cells; (6) eosinophils; (7) mast 
cells/basophils; and (8) neutrophils. Critically helminths have an effect on (9) allergy 
and (10) modulation of immune responses. 
 
Non-haematopoetic stromal cells, such as keratinocytes, epithelial cells and smooth 
muscle cells also play vital roles in helminth interactions due to their proximity to the 
infection sites. Epithelial cells are the first barrier layer exposed to the invading 
helminth (Figure 1.4). These cells initiate an alarm response releasing TSLP, IL-33 and 
IL-25 as well as some other alarmins [52]. This stimulates dendritic cells to mount a 
type 2 immune response and inhibition of IL-12 release [53], Th2 response 
downregulates the Th1 response and initiates the expansion of effector cell populations 
of ILC2s, basophils and mast cells. Smooth muscle cells contract, mucus production 
increases and fluids flow in the gut lumen, which contributes to "weep and sweep" 
action on the live adult pathogen [54, 55]. Smooth muscle cells are highly effective 
antigen presenters [56] which elicit robust Th2 responses [57] with the induction of 
lung pathology during N. brasiliensis infection recently attributed to IL-4Rα signalling 
on smooth muscle cells [58].  
 
Type 2 innate lymphoid cells, expand robustly in response to exogenous IL-25 or IL-
33, providing the critical linkage to adaptive defences [25]. Defined by their expression 
of IL-33 receptor (IL-33R) under the transcriptional control of GATA3 and RORα; 
ILC2s respond to activation by releasing type-2 cytokines IL-13, IL-5 but also IL-4, 
IL-9, granulocyte-macrophage–colony-stimulating factor (GM-CSF) and amphiregulin 
[26]. What proceeds is a potent induction of eosinophilia, mucus production (goblet 
cells), macrophage activation, smooth muscle contraction and tissue repair.  
There is considerable overlap between Th2 cell and ILC2s. The variant speed at which 
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each of these cell types releases cytokines (ILC2s are innate and rapid) and ILC2s 
ability to directly regulate T cell activation means that there is room for coordinated 
strategies for functionality. IL-13 and T cells are essential for worm expulsion, but T 
cell secretion of IL-13 is not necessary for expulsion [59]. The initial discovery of 
ILC2's came from rag knockout mouse models (RAG-1 deficient mice produce no 
mature T and B cells) [60] which, upon stimulation with IL-33 and IL-25, produced 
key type 2 cytokines chief of which were IL-13, attesting to the existence of another 
cellular mechanism which bypassed the adaptive arm of immunity [25]. After infection 
with N. brasiliensis, and they are the major innate IL-13 expressing cells. In the same 
model, a transfer of wild type ILC2 cells to rag knockout mouse rescued the anti-
helminthic response [61]. 
Interestingly reports have now linked ILC2s with metabolism. They affect homeostasis 
and are also more active in cases of obesity and starvation [62]. This could hint at a link 
through which helminths can modulate host metabolic function during colonization [63, 
64].  
Dendritic cells. Even though the classical mode of action for dendritic cells is the 
activation of T cell phenotypes Th1, Th17 and Treg, studies have shown that DCS is 
required for optimal Th2 responses in vivo. The depletion of DCs in both S. mansoni 
and H. polygyrus models inhibits the induction of Th2 responses [65]. The helminth 
products can prime DCs towards Th2 phenotype through its interaction with PRRs, 
TLRs and CLRs (C-type lectin receptors) and therefore suppress antigen presentation 
and the expression of Th1 cytokines through direct interference with the pathways. 
There is a general trend of modulation of DCs by helminths and this by default impairs 
their ability to defend against other infectious stimuli [65].  
 
Monocytes have emerged as facilitators of divergent immune functions during 
infectious disease with Turner et al. [12] suggesting both pro-inflammatory and anti-
inflammatory states for the monocyte, not unlike macrophage classification. 
Classification of monocytes by classical, intermediate or non-classical derives from the 
expression of CD16 and CD14 in monocytes circulating in peripheral blood. 
Interestingly, looking at the rough perimeters of the subsets, the grouping of monocytes 
would fluctuate based on a variety of factors and may influence STH infection 
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outcomes. Appleby et al. [66] also illustrated that CD16 (IgG receptor) expression 
increased with parasite-specific total IgG and IgG1 in healthy populations, and was 
associated with protection against schistosome infection. CD16 expression correlates 
with the pro-inflammatory phenotype of monocytes with cytokine secretion profile 
(TNFa in response to LPS) and ability to present antigen. By modelling the in vitro 
interaction between the filarial worm W. bancrofti and classical, non-classical and 
intermediate monocytes, the functional variation in response to helminth infection 
becomes apparent [67]. A notable association from this study was CD16 expressing 
monocytes with their ability to interact with a filarial antigen and simultaneous 
production of regulatory cytokines such as IL-10. Notably, the large proportion of 
human monocyte studies have not involved populations with direct exposure to tropical 
disease, where helminth infections are most prevalent. Instead, they have taken place 
in high-income countries reviewing non-communicable diseases [67]. To this effect, an 
African population negative for helminth infections, malaria and HIV, were compared 
to a Caucasian population. Changes in expression intensity of monocyte markers based 
on ethnic background were reported, highlighting the need to diversify monocyte 
studies [67].  
Macrophages are an essential class of antigen-presenting cells that serve as protector 
cells in parasitic infections. The polarisation of macrophages is mediated by the types 
PAMPs (pathogen-associated molecular patterns) and cytokine profile it receives. 
Helminth interaction produces a population of Alternatively activated macrophages 
(AAMs or M2), which are defined by their expression of arginase instead of nitric 
oxide, are rapidly recruited to the sites of helminth infection during Th2 immune 
response [5-7] triggered by IL-4, IL-13 and IL-10 [4, 8] and increased mannose receptor 
(CD206). Their primary functions during helminth infection involve the down-
regulation of Th1 response through IL-10 [9] [7] and wound healing caused by parasite 
migration [10]. For example, H. polygyrus is mediated by IgG-dependent induction of 
arginase in AAMs [68] and SP-D directly interacts with N. brasiliensis and lung 
macrophages that polarise macrophages to AAMs in the lung [69].  
T cells. Helminth infections typically produce a robust immune response that enhances 
the expression of IL-4, IL-5, IL-9, IL-10 and IL-13. The central cells are the CD4+ Th2 
cells expressing IL-4Rα, which is a component of both IL-4 and IL-13 receptors is at 
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the centre of Th2 immunity [70]. IL-4 and IL-13 are separated by expression in the 
body, with IL-4 being pronounced in the lymph nodes and IL-13 being pronounced in 
the tissues. IL-4 is a critical CD4+ T-cell cytokine, which, when released, can 
sufficiently support Th2 cell expansion during N. brasiliensis infection [71]. Aside 
from the classical Th2 activation, there are other T-cell activation states present in 
helminth infection; a new subset of T cells that expressing IL-9, IL-10 and no IL-4 has 
been described in allergy and intestinal helminth infection [72]. Th9 cells are associated 
with host protection in N. brasiliensis and T. muris infections. Th17 cells express the 
cytokine IL-17 that in helminth infection models (i.e. S. mansoni) has been associated 
with immune-mediated pathology [73].  
A strong example of host-parasite compromise comes from CD4+ T-cells response in 
schistosome infection, whereby the stimulation of parasite development and 
inflammation is required for migration of the eggs [74] but granuloma formation in host 
gastrointestinal tract and liver allows the eggs to mature but protects the host from 
severe inflammation. In mouse models, this is illustrated when the balance is not 
achieved, resulting in severe mouse pathology stemming from unchecked activation of 
CD4 Th1 and Th17 cells [75]. 
Cytokine responses initiated by Th2 cells promote effector functions in both bone 
marrow-derived haematopoietic cells and non-bone marrow-derived cells and tissues. 
Helminths can potentially function as a type of adjuvant, enhancing or shifting bodies 
response to antigen, with recent studies showing their role in Th2 differentiation to non-
helminthic antigens [71] [76]. Interestingly, the linkage between the innate and adaptive 
arms of immunity comes from the crosstalk between ILC2s and CD4+ T-cells, 
respectively. Both arms are critical in helminth expulsion, but the very recent discovery 
of ILC2s means the exact mechanisms by which it communicates with adaptive cell 
populations is as of yet undetermined.  
B-cells are activated and produce associated cytokines, namely IL-10 (an anti-
inflammatory cytokine that inhibits Th1 cells, NK cells and classical macrophages [77]) 
and IL-2 (supports correct development of effector and memory Th2 cells [78]). 
Secondly, their most notable role is at the level of antibody production. Infection with 
protozoan parasites leads to the production of IgG and IgM, with helminths, there is 
additional production of large amounts of IgE [79]. Antibody acts to; neutralize 
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parasites by binding to, or blocking the function of various cell surface markers, recruit 
phagocytic cells to the site of infection and trigger neutralization through complement 
activation [79]. 
IgG is the primary antibody present in human sera functioning to activate complement 
and bind to the parasite, marking it for phagocytosis. It is mostly present towards the 
end of infection is responsible for antigen-specific neutralization of 'known' parasites. 
Chronic helminth infection elevates subtypes of IgG, namely IgG4 and IgG1 [80] [81]. 
IgE functions as a parasite and allergen-specific immune effector; it's the least abundant 
in human sera but elicits some of the most potent inflammatory reactions [82]. Like 
IgG4, IgE's production is dependent on the release of Th2 cytokines IL-4/IL-13 from 
CD4+ T-cell and ILC2s. However, IgE is a lot faster and short-lived. IgE plays 
important roles not only in infection of multicellular organisms (i.e. helminth infection) 
but also in allergic conditions due to its high-affinity binding of Fc receptor on both 
mast cells and basophils, triggering their effector functions [83].  
Interestingly, parasite-specific IgE in patients' sera, has been associated with natural 
resistance to infection [84] or re-infection [85] [86]. IgG4 is the rarest subtype of IgG 
and only forms when antigen persists. Therefore IgG4 relates to a long term 
asymptomatic or chronic infection, competing with the same epitopes as IgE it perhaps 
mediates a long term massive allergic/inflammatory response [87]. The co-evolution of 
parasite and human immune interaction could be at play here, with a long term survival 
strategy for helminths involving the elevation of IgG4.  
Eosinophils in systemic circulation sharply increase in the early response to helminth 
infection [88] being rapidly recruited to the site of infection mediated by IL-5. This 
increase, both in blood and tissue, falls under the influence of ILC2s. Their effector 
functions involve the rapid release of immunomodulatory factors including cytokines, 
chemokines and growth factors through which they mediate IgE production and goblet 
cell mucus production [89]. New eosinophil functions have uncovered a more subtle 
immunomodulatory role in mouse models, supporting nematode larvae survival by 
promoting Th2 cell accumulation and preventing macrophage or neutrophil induction 
via iNOS [90]. Eosinophils do mediate the damage during N. brasiliensis challenge in 
the absence of CD4+ T cells [59] although the primary response to the nematode is 
unaffected in an eosinophil-depleted mouse model [91]. They are also powerfully 
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linked to host resistance to helminths and allergic inflammation, including asthma [92] 
[93].  
Basophils, like eosinophils, increase in number during helminth infection; they are 
essential in helminth infections secreting histamines, cytokines (an important source of 
IL-13 and IL-4) and lipid mediators all to promote Th2 response [94]. They are antigen-
presenting cells that drive Th2 cell differentiation and generate large amounts of IL-4 
in both an IgE dependent and independent manner [94]. Basophils, therefore, play a 
role in primary infection resistance in secondary infection protective immunity. In 
infection with N. brasiliensis basophils are found dispersed throughout the lungs, 
spleen and liver [95]. The release of IL-4 during early infection aids in Th2 activation 
and up-regulation [95].  
Mast cells are a potent arm of the inflammatory response in innate immunity. They 
reside in peripheral tissues, making them an immediate responder, expressing an Fc 
receptor that is sensitized with antigen-specific IgE [96]. Basophils and mast cells both 
share expression of Fc receptor for IgE as well as TLR2 and TLR4 and also release IL-
4 due to activation, but mast cells differ in their rapid speed of activation [97]. Hepworth 
et al. [98] have recently shown that mast cell degranulation is required to enhance the 
expression of tissue cytokines IL-25, IL-33 and TSLP during early helminth infection 
which primes type 2 immunity. They are also classically considered alate-stage effector 
cells that crosslink antigen-specific IgE and cause degranulation [42]. The type of mast 
cell response correlates with distinct microenvironments that nematodes colonize, H. 
polygyrus and N. brasiliensis colonize the intestinal lumen whereas T. spiralis inhabits 
the intestinal epithelium (arguably where mast cell action becomes more vital and 
effective) [45]. 
Neutrophil recruitment to a helminth invasion site has also been demonstrated [5] and 
is thought to be, along with macrophages, part of the team of first responders that 
contains or destroy parasites. Recently Chen et al. demonstrated, using a N. brasiliensis 
mouse model that neutrophils in parasite-infected mice showed a distinct 
transcriptional profile that promoted alternatively activated macrophage polarization 
through the secretion of IL-13. Therefore a distinct activation state for neutrophils, in 
the context of type 2 immune response, primes a macrophage phenotype that directly 
mediates rapid nematode damage and clearance [99]. 
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1.2.4 C-type lectins and helminth infections 
There is evidence to suggest that C-type lectins play a role in driving helminth immune 
responses [100]. Lectins are abundantly present on immune cells and with their 
structural commonality being that they share at least one or more C-type lectin domain 
(CTLD), which determines its carbohydrate specificity. These families of calcium-
dependent receptors are abundantly present on immune cells, and in the 
microenvironment, collectively, they recognize a variety of glycan's (abundant on the 
surface of helminths) [101]. Examples range from mannose receptor (CD206), which 
is a surface receptor found on the surface of macrophages, all the way to a soluble 
receptor-like surfactant protein D. Increasing our understanding of how these molecules 
interact with immunity and pathogens, or beneficially modulate inflammation could 
help future research surrounding treatment and interventions. 
1.3 Atopy  
1.3.1 Introduction to atopy and atopic dermatitis  
Allergies or atopy are inflammatory disorders where the immune system recognizes 
non-harmful environmental stimuli as pathogenic and generates an inappropriate 
immune response. Allergen-specific responses are initiated via the response of CD4+ 
Th2 cells, ultimately driving the production of allergen-specific IgE that leads to 
memory [79]. An individual with an unusual IgE or sometimes IgG response is deemed 
'sensitized', and exposure to an allergen leads to diseases such as asthma, atopic 
dermatitis, allergic rhinitis and food allergy [79].  
 
Allergy prevalence has significantly increased over the last 50 years, with more than 
30% of children allergic, 10% of children having asthma and allergic rhinitis, and 5-
7% of children with food allergy [102]. Queue the hygiene hypothesis, the idea that a 
lack of early childhood exposure to pathogens, healthy microbiota and parasites 
increases susceptibility to allergic disease because of suppression of the development 
of immunity [103, 104]. However, meta-analysis and grand assumptions made over the 
hygiene of third world environments is controversial and sometimes inaccurate. An 
extension or shift from this is the old friends' hypothesis, which states that increase in 
allergic disease is due to a loss of symbiosis between the human biome and parasites 
and bacteria, which were once evolutionarily beneficial [105].   
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The concept of atopic march describes the sequence and progression of atopic disorders 
from atopic dermatitis in infants on to food allergy, allergic rhinitis, and then eczema 
later as children. To understand the interplay between helminth infection immunology 
and allergic disease, the context of child age and progression of allergic disease must 
be taken into account (Figure 1.5).   
	
Figure 1.5: The allergic march during childhood. Progression of atopy from birth to 15 years old with 
different allergic disease appearing at different ages beginning with atopic dermatitis (eczema), on to 
food allergy, rhinitis and then asthma. This is just a representative plot, and there is much overlap in 
disease (adapted from LEAP study, 2011).   
1.3.2 Atopic Dermatitis  
Atopic dermatitis (eczema) is a particular chronic inflammatory disorder (allergy) that 
affects the skin. The resultant inflammation leads to itchy, red and swollen lesions on 
particularly sensitive areas of the body. The condition can occur at any age but is most 
commonly developed in children (see figure 1.5). The risk of concurrent development 
of other allergic conditions is also increased (see figure 1.5). SCORAD (SCORing 
Atopic Dermatitis) is a test to assess the severity of atopic dermatitis as objectively as 
possible; the scale runs from 0-100 based on various metrics surround size, 
inflammation and discomfort of lesions [106]. It is a useful benchmark for 
understanding the individual severity of atopic dermatitis and can be directly compared 
to SP-D to assess for any associations.   
 
The causes root in genetics, environmental exposure and skin permeability issues that 
cause immune dysfunction leading to chronic inflammation. Mutations to the gene 
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encoding for filaggrin (FLG), which among many things ensures a well-functioning 
and hydrated epidermis, have been heavily associated with the development of AD 
[107] [108]. Interestingly, the discovery of faulty production of FLG indicates that AD, 
rather than just a primary immune problem, revolves around the structure and function 
of the barrier itself and causes resultant immune inflammation. The FLG mutation is a 
significant risk not only for AD but for all aspects of atopy (rhinitis, asthma, food 
allergy), illustrating how heavily interlinked allergic diseases are	[108]. This supports 
the model that skin barrier dysfunction is a key driver in allergic disease and the onset 
of AD, or skin barrier dysfunction leads to allergen exposure and is the first step in a 
cascade of inflammatory disorders	[109].	  
1.3.3 Helminth infections, allergy and the modulation of immunity 
Chronic hookworm infection (Necator americanus) protects against asthma, but 
roundworm (Ascaris lumbricoides) infection aggravates allergic disease [110]. It is 
shown that repetitive anti-helminthic treatments to children in endemic areas produce 
an increase in allergen skin test reactivity [111] and that children in helminth endemic 
areas might have lowered risk of the development of allergy [111]. Study variation and 
conclusions could reflect a wide array of factors relating to species of helminth, the 
intensity of helminth infection, type of allergic disease and timing of infection 
concerning immune maturation. There is compelling evidence that suggests a switch in 
immune responses, from the initial onset of acute helminth infection with early 
exposure driving inflammatory response, creating an allergy, to the classic long term 
chronic response that attenuates host inflammation and allergy [112] [113]. 
 
The helminth-mediated modulation of allergic responses is hugely complex. 
Consideration must be made for the type of helminth, secreted products, site of 
infection and the local microbiome. Studies have observed various mechanisms at play. 
IL-10 induced suppression of Th2 polarisation and expansion of Treg cells (both natural 
and parasite-induced) [114]. IL-10 inhibition of IgE signalling in basophils, which, as 
previously mentioned, are important players in an allergic response. Upon helminth 
infection, B-cells differentiate into a regulatory B-cell type that produces IL-10, which 
would suppress Th2 response and expand Treg cells [115]. Parasites drive the effect of 
Treg cells by secretion of TGF-β clones that bind to TGF-β receptors triggering Treg 
cell (FoxP3+) expansion [116]. In H. polygyrus infections (mouse modelled), type 2 
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immune response is downregulated by secretion of Hp-secreted protein, which inhibits 
IL-33 release [117].  
 
The local microbiome interaction with helminths and their secretory products must also 
be considered. The capacity of an allergen to cross a mucosal barrier is dependent upon 
the condition of the epithelial barrier with mucosal layer formation and anti-microbial 
peptide release mediated by IL-22 [118]. These are released by healthy mucosa-
associated bacterial communities, compositional changes within these communities 
through things like diet or antibiotic use could alter the bacterial induction of protective 
mucosal responses, which could lead to type 2 inflammatory response [119]. This is 
another example of the intertwined co-evolution between helminths and human 
immunity, with the modulatory response of the helminth or their derived proteins 
contributing indirectly to the modulation of allergic response. 
 
There is also evidence to suggests that some parasitic helminths or systemic treatment 
with helminth products can lessen atopic disease and autoimmune disorders, e.g. 
Irritable bowel disease	[120]	[121], multiple sclerosis	[122]	[123] and arthritis	[124]. 
The hypothesis being that if immune modulation of helminth infection strikes a 
particular balance, inducing no obtuse pathology, helminths function almost like 
commensal organisms and not pathogens that need to be removed.  
1.4 Lung immunology 
1.4.1 Lung structure and function 
The lungs are the major organs of the respiratory system housing the mechanics 
required to facilitate gaseous exchange. A process by which the oxygen is filtered into 
the body and carbon dioxide is filtered out. This process happens over a vast epithelial 
surface area (+- 70m2) that is highly permeable to gases. The lungs transfer air from the 
conducting zone, where the air is funnelled through, into the respiratory zone, where 
gaseous exchange takes place. The exchange centres on the basic unit of ventilation 
known as alveoli (300-500 million in the adult lung), which are sacs that expand and 
contract during inhalation and exhalation [125]. These alveoli have a single layer of 
epithelium consisting of two different cell types; type 1 epithelial cells (single-layered 
and squamous) take up the most surface area and facilitate the gaseous exchange; type 
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2 alveolar cells are the most numerous but take up a fraction of the space. Type II 
alveolar cells (AT2 cells) perform a vital maintenance function through the release of 
pulmonary surfactant [126]. Pulmonary surfactant is a lipoprotein complex, made up of 
mostly phospholipids (dipalmitoylphosphatidylcholine), neutral lipids (cholesterol) 
and the proteins SP-A, SP-B, SP-C and SP-D. Surfactant contains both hydrophilic and 
hydrophobic domains, organizing in such a way that causes adsorption to the inner 
surface of the alveoli [125]. This adsorption fulfils its primary function, to decrease 
alveolar surface tension, stopping the collapse and allowing for the easy re-expansion 
of the alveoli on inhalation [127]. This function is performed by 2 of its subcomponents 
surfactant protein B (SP-B) and surfactant protein C (SP-C), which are hydrophobic, in 
conjunction with the phospholipids to optimize surfactants adsorption [128]. The other 
2 subcomponents, known as surfactant protein A and surfactant protein D, are collectins 
(collagen-containing C-type lectins) that form a niche part of innate lung immunity 
through their interaction with pathogens [129]. 
1.4.2 Lung immunology  
Immunity in the context of the lung is a double-edged sword. It faces the dual task of 
maintaining an inflammation free mucosal surface whilst still eliminating inhaled 
pathogens. Fine-tuned maintenance of this pulmonary homeostasis is critical to our 
survival, with any breaks in gaseous exchange due to inflammation or illness being life-
threatening. Physical barriers are designed to filter out most of the inhaled material. 
However, a large proportion of small (<5um) infectious or allergenic particles still 
reach the distal air spaces. In a functional lung, the particles would then encounter 
components of the innate immune system including alveolar macrophages, dendritic 
cells and lung collectins [125]. The ability of the lung to remain infection and 
inflammation free is due to the small family of calcium-dependent C-type lectins. SP-
D and SP-A are expressed on most mucosal surfaces but exist at much higher 
concentrations in the lung [129]. SP-A knockout mice display no lung pathology; 
however, SP-D knockout mice show chronic inflammation, highlighting the niche role 
for SP-D specifically regarding the inflammatory homeostasis of the lung and 
communication with innate immune cells [129].  
 
SP-D is structured as a large hydrophilic protein with an N-terminal triple-helical 
collagen region and a trimeric ligand carbohydrate recognition domain, called a C-type 
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lectin [130]. The direct mechanism of modulation is unclear, but the C-terminal lectin 
end of SP-D is involved in suppression of immune cell activation, therefore suppressing 
inflammation itself, with the N-terminal collagen domain facilitating the clearance of 
pathogens and apoptotic cells through phagocytosis [131]. This is further complicated 
by the fact that SP-D modifies grouping structure based on oxidative changes in the 
lung environment as well as genotype of the protein [132].  
1.4.3 Surfactant protein D and its role in helminth infections 
The type 2 immune cascade in helminth infection involves damage to the epithelial 
layers in the body. Figure 1.4 shows that epithelial damage leads to the release of IL-
25, IL-33 and TSLP, which triggers the downstream activation of effector populations 
in an attempt to expel the helminth. As previously mentioned, in helminth infections 
involving lung colonization, the primary cell type releasing IL-33/IL-25 and priming 
anti-helminthic responses are alveolar type II cells (ATII cells) [133]. Another major 
immunomodulatory protein released by ATII cells is surfactant protein D (SP-D). 
Classified as a hydrophilic pulmonary collectin (soluble C-type lectin), as previously 
stated, SP-D plays a vital role in the modulation of mucosal immunity during exposure 
to microbes [134]. 
 
Figure 1.6: Surfactant protein D levels are increased and protective following Nippostrongylus 
brasiliensis infection. SP-D levels are significantly increased in bronchoalveolar lavage (BAL) 
following primary and secondary N. brasiliensis infection (A). Intranasal administration of SP-D to naïve 
mice reduces host-parasite burden (Bi) and associates with increased protective ILC2 (Bii) and IL-33 
responsive activated CD4+ T-cell populations (Biii). Figure sourced from our lab at UCT [69]. 
SP-D binds directly to helminths such as Schistosoma mansoni [135] and allergens 
protecting host lung from asthma [136]. A STAT6 knockout murine model shows 
greatly reduced SP-D titres [137] demonstrating its induction is dependent on type 2 
immune activation. Recently, data emerging from our research group at UCT [69] links 
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the specific control of mouse-modelled nematode infections with SP-D. The research 
demonstrated that infection with N. brasiliensis correlated with increased lung SP-D 
levels (Figure 1.6A) and the administration of recombinant SP-D protects against N. 
brasiliensis infection by reducing worm burden (Figure 1.6Bi). This protection is 
associated with increased populations of ILC2s and CD4+ T-cells (Figure 1.6Bii and 
Figure 1.6Biii)) 
 
Figure 1.7: Nippostrongylus brasiliensis incubated with recombinant surfactant protein D. 
Illustrating the interaction of SP-D with the L4 lung stage of an N. brasiliensis infection Figure sourced 
from Thawer et al. [69].  
As a C-type lectin, SP-D includes an N-terminal triple helix collagen region and a 
carbohydrate recognition region (CRD) [138], functioning as an immunomodulator 
with an affinity towards various immune cell types [139]. Both surfactant protein A 
(SP-A) and SP-D are essential in defence against respiratory pathogens and allergens 
[140] [141]. SP-D's helminth pathogen recognition abilities fall under the influence of 
Th2 cytokines such as IL-4, IL-13 and TNFα [142]. Unlike its counterpart, SP-A, which 
is at its highest levels in the alveolar epithelium, SP-D is found at its highest levels in 
bronchoalveolar lavage fluid (BALF) (75%) [143]. This could be due to SP-D's role in 
immune responses towards extracellular pathogens and SP-A's role in immune response 
towards intracellular pathogens. Due to the size and nature of helminth infections in the 
lung, the interface with effector molecules such as SP-D would be more critical 
extracellularly, at epithelial surfaces, explaining the heightened concentration of SP-D 




Figure 1.8: The structure and formation of surfactant protein D. The structure and formations of 
surfactant protein D. Surfactant protein D is a large hydrophilic protein known as a C-type lectin. Its 
basic subunit contains an N-terminus, a helical collagen region and a ligand carbohydrate recognition 
domain. Dependent on environment and genotype, SP-D can group as a trimer or multimer, which 
determines its recognition and interactions to pathogens, allergens and immune mediators. Diagram 
created by Zoe Baker.  
Other C-type lectins also show roles in helminth infections with Ritter et al. reporting 
on schistosomal egg antigens that interact with the C-type lectin, dectin 2 [144]. There 
is also membrane surface receptor CD206 (mannose receptor) mentioned earlier. This 
molecule is key in the kinase signalling pathway and induces potassium efflux and the 
production of ROS, ultimately decreasing the immunopathology of Schistosome 
infections [144]. A knockout model of another C-type lectin, mannose-binding lectin-
A, showed mice with irregular IgM responses that exhibit increased susceptibility to 
nematode infection [145]. Evidence of other C-type lectins and their immune 
interactions coupled with the established presence of SP-D, not only in the lung but 
other peripheral tissues and mucosal surfaces alludes to its powerful role in innate 
immunity outside of the pulmonary environment [130].  
 
As previously stated, SP-D modifies grouping structure based on oxidative changes in 
the lung environment [132]. Normal lung environments suppress phagocytosis, 
retaining the ability to perform effective gaseous exchange, and an inflamed lung will 
promote apoptotic cell clearance. A key determinant is SP-D's grouping structure and 
the orientation by which it binds to effector cells [146]. SP-D induces a classically anti-
inflammatory phenotype which is important in mucosal barriers, such as the lungs, 




































inflammatory role can be assumed to aid immune activation [147]. For various reasons 
(low protein concentration, biochemical modification and proteolytic breakdown) SP-
D can decompose from multimeric form to low molecular weight (LMW) forms [148]. 
This decomposition can induce pro-inflammatory signalling, which is characterized by 
binding to LPS and lipoproteins [129] to a more considerable degree than HMW SP-D. 
SP-D shares characteristics with both under- and overexpressing macrophage models 
[131], with Clark et al. supporting this information showing 10 fold increase in 
apoptotic alveolar macrophages in SP-D knockout mice, with a reduction coming from 
the administration of recombinant SP-D [149]. The model for how SP-D operates in 
the lung remains type 2 driven and anti-inflammatory, with this inflammatory 
phenotype only generated under very specific circumstances. 
1.4.4 Surfactant protein D and its role in atopy 
As previous stated SP-D has been implicated in various respiratory diseases, including 
pulmonary dysplasia, allergic asthma, and chronic obstructive pulmonary disease. The 
abnormal modification of the pulmonary environment leads to the breakdown or 
modification of SP-D; this changes its homeostatic balance and can shift the lung into 
a different inflammatory state. Phenotypic characteristics of SP-D in asthma include 
increased systemic SP-D levels, which could be due to the induction of SP-D synthesis 
in airway epithelia and the change in barrier integrity [150]. This shift in structure leads 
to systemic leakage from the lung, increasing serum SP-D concentration, the systemic 
effects of which are unknown. This also proves to be a promising biomarker for lung 
injury. SP-D levels are increased in cases of severe allergic asthma [151] and are 
correlated with BAL eosinophils and neutrophils. These BAL eosinophils are in turn 
correlated with NO content and the level of oxidized SP-D species, which, as previously 
stated, could affect the inflammatory profile of SP-D. As stated above the variability of 
oxidation state changes the inflammatory effect of SP-D.  
 
The serum concentration of SP-D rises in asthma [151]	[152] but also allergic rhinitis, 
which has the same underlying disease process as asthma, involving the respiratory 
tract and its adjuncts [153]. Research demonstrates the link between SP-D and Th2 
mediated inflammation associated with allergy, which is modelled not only in murine 
allergy models but also human data [153]. However, there is substantial variation in 
clinical data; it is postulated that this is due to a lack of sample stratification. Allergy 
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can be characterized based on its up-regulated Th-2 profile, and in murine allergy, 
models using Sftpd−/− mice as allergic asthma models, the administration of both SP-D 
and rfhSP-D appear to dampen aspects of the allergic phenotype	 [154]. In murine 
models of hypersensitivity induced by allergen challenge, administration of both SP-D 
and rfhSP-D suppress IgE (antigen-specific) in serum, reduces eosinophilia and causes 
Th-1 cell polarisation [155].  
 
Allergen-specific responses are initiated via the response of CD4+ Th2 cells, ultimately 
driving the production of allergen-specific IgE that leads to memory [79]. An individual 
with an unusual IgE response is deemed 'sensitized', and exposure to an allergen leads 
to diseases such as asthma, atopic dermatitis, allergic rhinitis and food allergy [79].In 
humans, the loss of barrier integrity associated with respiratory disease can cause 
pulmonary SP-D to leak into serum; this detectably increases serum SP-D. This leakage 
changes the ratio of BAL SP-D to serum SP-D and is effective in determining certain 
disease types. One major issue is the invasive nature of BAL SP-D sampling; it limits 
the use of this ratio in wide-scale disease monitoring	[156].  
Therefore it is observed that SP-D is not only as a marker for asthma and rhinitis but 
also as a functional suppressant of hypersensitive allergic responses. The protective 
mechanisms by which SP-D suppresses allergenic challenge involves various levels; 
direct interaction with an allergen, crosslinking IgE and allergen with histamine release, 
important immune cell suppression (mast cells and eosinophils), suppression of T and 
B cell proliferation and modulation of DCs and macrophages	[141].  
1.5 IgE-IgG4 BALANCE in allergy and helminth infection 
The complex cascade of immunoglobulins at various intervals has led to the proposal 
for a time mediated model of human IgE and IgG function [157] with the persistence 
of the antigen finally stimulating high-affinity IgG4 that outcompetes other isotypes 
and can terminate IgG1-mediated activation via the inhibitory FcγRIIB [31]. The basic 
effect of Th2 cytokines IL-4 and IL-13 on B-cells during clonal expansion induces the 
switching of immunoglobulins to IgE but also IgG4	[158]. The research suggests that 
during helminth infection, immune responses and hyper-reactivity is mediated by a 
balance of parasite-specific IgE and IgG4.  
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There are two mechanisms by which this would occur; firstly because plasma cells 
switch sequentially from producing IgM via IgG4 to IgE [33], a cessation of class 
switching would lead to a cessation in production of IgE expression at germline. 
Secondly, IgE is bound to high-affinity Fcɛ receptors on cells (basophil, eosinophil, or 
mast cell) [83], and IgG4 is free in serum	[80]. IgG4 as a subclass functions as a sort of 
'blocking antibody' resulting from its direct competition with IgE for antigen binding 
in serum, when both isotypes are close to helminth antigen. IgG4 does not fix to 
complement and binds weakly to Fcγ receptors [159] therefore when it outcompetes 
IgE (bound to functional immune cells) it causes minimal or very small consequences, 
therefore down-regulating the effects of antigen-specific IgE. In patients with 
lymphatic filariasis even though IgE is associated with natural resistance to infection 
[10,11] or re-infection [12–14] elevated levels of IgG4 is related to asymptomatic 
infection state, with IgG4 competition with IgE leading to this [15,16]. This points to a 
mechanism by which IgG4 enhances parasite survival by inhibiting IgE-mediated 
effector responses. 
 
Blockage of specific IgE antibody by IgG4 is not just at the level of helminth but also 
in allergy.  Allergic disease that is in a controlled phase is associated with the balance 
shifting towards increased allergen-specific IgG4 and decreased allergen-specific IgE 
[160]. The data suggests that this control is mediated through IL-10, which acts 
indirectly to modulate the production of IgE and directly on B-cells to drive IgG4 
production [160]. IL-10 has also been implicated in the dampening of allergic responses 
and increased production of allergen-specific IgG4 in patients receiving allergen-
specific immunotherapy [39]. The modified Th2 environment that is created by chronic 
helminth infection is also characterized by high levels of IL-10 secretion [40]. 
Therefore the elevation of IgG4 in the same environment indicates IgG4's direct 
involvement in the underlying regulatory response of chronic helminth infections.  
 
It is postulated that the balance of immunoglobulins IgE and IgG4 in helminth infection 
and allergy could have a role in determining long term infection status and 
hypersensitivity reactions. Research shows this effect in endemic areas of Ascaris 
infection. ABA-1 is an Ascaris protein and potent allergen, but immediate 
hypersensitivity reactions (characterized by pulmonary Ascaris syndrome) are hardly 
seen [161]. By contrast, in seasonal areas of Ascaris infection, immediate 
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hypersensitivity responses are more common [162]. The mechanism at play here that 
prevents widescale hypersensitivity in endemic areas has got to do with sustained 
chronic exposure to Ascaris [161]. The research postulates that a different balance of 
ABA-1 IgG4 and ABA-1 IgE expression exists. A larger quantity of specific IgG4 is 
important in limiting pathology, in endemic areas, but also enough specific IgE still 
allows for control of infection and limiting worm burdens.  
 
Interestingly, because of the tight immunomodulatory mechanism under which SP-D 
operates, and its link to type 2 immunity, could SP-D influence the IgE-IgG4 balance? 
SP-D binds to IgG, IgM, IgA, IgE, in a calcium-dependent manner [51], also 
specifically recognizing both Fc and Fab domains of IgG [147].  When IgG-coated 
beads were incubated with SP-D, the immune complexes formed large aggregates. 
Notably, macrophages avidly recognize these SP-D-induced IgG bead aggregates 
enhancing phagocytosis in murine macrophages [163]. Recent studies indicate that SP-
D is present in the blood, and its concentration in the serum is significantly determined 
by genetics [164]. The SP-D-IgG interaction and following enhancement of immune 
aggregation and phagocytosis provide a means by which IgG-mediated responses are 
amplified [163], not only in the pulmonary environment but at various other mucosal 
tissues.  
1.6 The old friend's hypothesis relating to regulatory DCs and the 
activation of TLR2 through SP-D 
As stated previously, the hygiene hypothesis is based on the premise that exposure to 
pathogens during development and life of immunity primes the immune system and by 
default limits unwanted hypersensitivity responses (allergic disease). The old friend's 
hypothesis elaborates upon that with the essential insight still being pertinent, microbial 
exposure modulates our immune system. The development of allergic disorders and 
exposure to childhood disease is a small part of a much bigger evolutionary story; the 
old friend's mechanism is a much broader term not solely based around allergic 
response. It encompasses the idea that there is a broad spectrum of interactions between 
mammals and their microbial environment. Mammalian microbial interactions fall 
along a spectrum from endosymbiotic to various microbiotas in physiology to harmless 
organisms' encounters (commensals) to dangerous pathogens. This type of microbial 
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interaction, with dangerous pathogens, forms the original basis for the hygiene 
hypothesis.  
 
The reasons for microbial exposure during youth are apparent in the sense that it 
provides signals for the development of the immune system. The more exposure to 
broad biodiversity of microbes builds up a repertoire of molecular structures that allows 
for more rapid detection of novel pathogens [165]. We also need background activation 
of innate immunity through microbial components such as LPS [166]. What is less 
obvious is that we also need to develop regulatory/control mechanisms to stop the 
immune system from becoming hypersensitive to inappropriate stimuli. If these 
regulatory mechanisms do not develop, we develop allergic disease [167] autoimmune 
disorders [168] and inflammatory gut diseases [169]. The rates of all of these conditions 
in high-income countries are increased. Therefore in areas that are classically defined 
as high income and urban, there seems to be a failure to shut off unwanted 
inflammation. Comparatively the low-income setting inflammation appears when 
needed but then is completely shut off when the immune threat (resolution of infection) 
has passed.  
 
Organisms with which we co-evolved, therefore, had to be tolerated to ensure the 
survival of mammal and microbe. These included commensals in the microbiome, 
harmless organisms from the environment and a specific set of infections. These 
include helminth infections because they cause non-fatal or subclinical carrier states. 
The molecules produced by helminth infections have unique mechanisms that drive 
regulation and specifically expand Treg populations and cause DCs to switch to 
regulatory phenotypes [116]. An example of this would be when patients with multiple 
sclerosis are infected with helminths, their rate of relapse slows or stops altogether, and 
this is associated with increased Treg (myelin-specific) cells in peripheral blood [170]. 
This identification of regulatory mechanisms for chronic inflammation is well 
supported by evidence, with 'old friends' driving this regulation. It is postulated that this 
is interrupted by a modern urban lifestyle shift, not only in geography but diet, exercise 
etc. The mechanism of activation involves selective activation of TLR2 by regulatory 
DCs; curiously another molecule that activates TLR2 is SP-D. What could the effect be 
of SP-D on this system?  
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1.7 Aims and objectives  
The first part of the work looked to identify if the key markers of protection identified 
in the mouse study are also found in human samples. It was hypothesized that there 
would be an overlap in the immunological effect between mouse and human protective 
immunity to helminth infections. It also looked at the atopic status and reviewed 
whether there was any influence on SP-D or helminth infection. 
 
1) Determine whether the exposure to a soil-transmitted helminth alters serum 
concentrations of surfactant protein D. For analysis 2 cohorts of bio-banked 
samples recruited in helminth endemic areas of South Africa were obtained.  
i. Cohort 1: Women from Masiphumelele, Western Cape. Collaboration 
with Assoc. Prof. Jo-Ann Passmore. University of Cape Town. 
ii. Cohort 2: Rural and Urban Children Eastern and Western Cape: 
collaboration with Professor M. Levine, Red Cross Children's Hospital, 
Cape Town, SOSALL 
 
2) Determine if there are any correlates of protection or exposure that exist in 
human serum from the cohorts mentioned above. In particular, the focus was on 
either marker of acute helminth exposure (i.e. participants with raised helminth 
specific IgE) or to markers of chronic helminth exposure (i.e. participants with 
raised helminth specific IgG4). 
 
3) Determine the role of atopy in the onset of helminth infection and functionality 
of SP-D in cohort 2. This will be a comparison of the prevalence of atopy and 
helminth infection.  
 
4) Determine whether helminth infection has an influence on atopic disease, 
specifically atopic dermatitis. This will be to determine whether the helminth 
infection influences the severity of atopy with particular focus on SCORAD 
(SCORing Atopic Dermatitis) values.  
 
The second part of the work looked to identify if SP-D influences the magnitude of 
anti-nematode responses in human immune cells. IT has been hypothesized that the 
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association between helminth exposure and SP-D relies on immune cell interaction, the 
mechanism for which is undefined, but could involve type 2 innate lymphoid cells 
(ILC2s), monocytes and macrophages.  
 
1) A robust method of review was setup for cellular phenotypes of ILC2's, 
monocytes and macrophages isolated from human PBMCs. Here flow 
cytometry was used to create a robust method of visualization due to the relative 
rarity of these immune cell types in human serum. 
 
2) This method will be used to review the influence of SP-D and helminth antigen 
and other cytokines on these immune cells. The aim was to review particular 
cellular phenotypes and how they shift under in vitro stimulation that mimics 
the basic interactions; of human peripheral blood mononuclear cells with 
Ascaris lumbricoides antigen and SP-D. With particular focus on the effect of 
the following combinations; (A) SP-D and Ascaris individually or combined on 
monocyte CD16, (B) SP-D and Ascaris individually or combined on 
macrophage CD16, (C) SP-D and Ascaris individually or combined on 
macrophage CD206. It is worth noting that time constraints did not allow for 




2 Materials and methods 
2.1 Ethics and recruitment for human work 
All experimental procedures were carried out in accordance with protocol number 
066/2015 (SOSALL cohort) and 258/2006 (Masiphumelele cohort) and approved by 
the university of Cape Town Faculty of health science human research ethics 
committee. 
 
The first cohort originates from Masiphumelele in Cape Town surrounds, a research 
project in collaboration with Associate Professor Jo-Anne Passmore (UCT) focusing 
on a cohort of 48 HIV- women [171].  
 
The second cohort, SOSALL, aims to review helminth infection and sensitisation in 
rural and urban Xhosa children with or without atopic dermatitis. It is a nested case 
study with selected 12-36 month Xhosa children recruited from both urban (Red Cross 
War Memorial Children’s Hospital, Cape Town) and rural environment (Nelson 
Mandela Academic Hospital, Eastern Cape) with a positive diagnosis of atopic 
dermatitis (AD), using scoring atopic dermatitis (SCORAD) method [172]. Age-
matched control participants from rural and urban cohorts of SAFFA (South African 
Food Allergy study) were then recruited. These recruits had no evidence of atopy or 
food allergy. Figure 2.1 is a visual representation of recruitment, 220 participants 
recruited with stool available from 158 and serum available from 129.  
 
Prior to this work, stool samples were analysed for worm ova and parasite load (Kato 
Katz examination kit, Vestergaard-Frandsen). Ascaris sensitisation determined 
measuring Asc-specific IgE (ImmunoCAP, ThermoFisher). Anti-Ascaris IgE levels of 
>0.35 kU/ℓ were considered positive. 
 
Human PBMC (Peripheral blood mononuclear cell) samples obtained from four blood 
donors, two male and two female, in the form of buffy packs from the Western Province 





Figure 2.1: Visual representation of SOSALL cohort structure. A sample pool of 50 children was 
selected from rural (Nelson Mandela hospital) and urban (Red Cross hospital) locations that were atopic 
dermatitis positive (Skin prick test larger than 3 mm). The umbrella SAFFA study provided rural and 
urban control children that were atopic dermatitis negative. 
2.2 Live worm and antigen preparation 
To assess cellular responses to specific helminth infection in vitro, two different forms 
of antigenic stimulation were created.  
  
Ascaris homogenization  
The first type of helminth antigen used was created through the emulsification of 
Ascaris worms harvested from the small intestine of infected children at Red Cross 
Children’s Hospital, Cape Town. These samples were then frozen at -80°C until 
needed. On-demand Ascaris worms were thawed added to an aliquot of Pen-Strep (10x) 
and fungizone and incubated for 1 hour. Segments from each worm were dissected and 
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pooled together in 50ml falcon tube with the remainder of worms frozen at -20°C for 
future use. Segments of the worm are mixed with PBS and homogenised to smooth 
“milkshake” consistency. Homogenous mix aliquoted into 2ml tubes and centrifuged 
at 1000g for 30min, supernatant sucked off and pooled into Eppendorf tubes. BCA was 
then performed to determine protein concentration. Samples then aliquoted and frozen 
at -80°C for use when necessary.  
 
Ascaris larvae hatching 
Larvae harvested from pig faeces on a Swiss farm and removed from sample tube using 
a serological pipette (add to 50ml falcon). Sample centrifuged at 500g for 5min and 
then resuspended in gravel media in falcon tube on the side and taped to shaker. 
Concentration calculated and the remainder of the sample containing eggs added to a 
flask of hatching beads (these are glass beads that slowly break away capsule 
surrounding eggs) with a magnetic stirrer for 10min. The magnetic stirrer moves very 
slowly, and this ensures the eggs hatch open but sensitive larvae are not destroyed. 
Check larvae under a microscope (+-80-90% eggs hatched is considered a good yield). 
Live worms are then used as a stimulant for in vitro cellular assays.  
2.3 Western Blot 
To assess variation in human Surfactant protein D levels with high specificity, a western 
blot analysis was performed. The kit used contained all hardware necessary (Mini-
PROTEAN® Tetra Cell, Bio-Rad Laboratories, Inc.). The running and stacking gel was 
made as a 1mm 10% reducing gel. Human serum samples standardised by nanodrop in 
order to ensure that 10ug protein loaded per well. Samples diluted in PBS according to 
protein concentration and 10ul was removed and combined with 10ul SDS running 
buffer. The samples were then centrifuged and placed on a heat block at 90°C for 5min 
to ensure the reduction of proteins. Samples were then loaded, and then gel 
electrophoresis was performed at 100V for 15min and stepped up to 200V for 20min. 
The electrophoresis was then stopped and running buffer discarded. 
 
The gel was then gently removed from gel cassette stand taking care not to touch or 
tear it. Layering the following made the sandwich for gel transfer: sponge, filter paper, 
gels, nitrocellulose, filter paper, sponge. This was then placed back into a mini tank and 
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submerging in transfer buffer. They were transferred for 1 hour at 100V. Once 
transferred, the nitrocellulose is removed from the sandwich and covered in ponceau 
stain, which indicates the presence of protein on the membrane it was then rinsed in 
blocking buffer (2% Milk Powder in PBS with and 0.1% tween20). The membrane was 
then topped up with blocking buffer and incubated for one hour. The membrane was 
then washed three times (10min each) with PBS 0.1% tween20 at room temperature on 
a shaker. Primary antibody was diluted (1:1000) in 5% milk powder (milk powder into 
1x PBS and 0.1% tween20) and incubated at 4˚C overnight on a shaker. Wash step was 
repeated as above. The secondary antibody (1:5000) was diluted in 5% milk powder 
(milk powder into 1x PBS and 0.1% tween20) and incubated for 1 hour at room 
temperature. The chemiluminescent signal generated through the addition of LumiGLO 
substrate (Protein Detector™ LumiGLO® Western Blotting Kit, KPL). Detection and 
densitometry performed using BioSpectrum® Imaging System, UVP. 
 
The SP-D western blot on human serum had not been performed in our laboratory 
before; therefore, the protocol had to be optimised to the sensitivity of the antibodies 
provided by Professor Howard Clark’s lab in Southampton. Initially, the secondary 
antibody overdeveloped with a large amount of non-specific binding, above what 
should be expected in human serum western blots [173]. Some notable improvements 
upon this experiment include the following; addition of positive control for SP-D to 
quantify the samples directly; although samples were nanodropped and standardised to 
10ug protein loaded per well the addition of loading control to ensure consistency in 
protein loaded.   
2.4 Enzyme-linked immunosorbent assay (ELISA) 
Human serum samples from a cohort with known IgE specific Ascaris and IgG4 
specific Ascaris titers were quantified by sandwich ELISA to assess Surfactant protein 
D levels. The capture antibody (rabbit polyclonal anti-human SP-D antibody) was 
diluted at 1:1000 (stock 1.61mg/ml) in carbonate buffer (pH9.6), this was added at 50ul 
per well to 96well plates (Nunc Maxisorp; Thermo Fisher Scientific) and incubated 
overnight at 4°C. The plates were washed four times with wash buffer. Unbound sites 
were blocked using 200ul per well, of blocking buffer (2% Milk Powder in PBS) and 
incubated for 3 hours at 37°C. Wash step was repeated. The sample was then added at 
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50ul/well at dilutions of 1:4, 1:12, 1:48 in dilution buffer. The standard, rfhSP-D, was 
added with a starting concentration of 500ng/ml and titrated out (five-fold dilution 
series). They were incubated overnight at 4°C. The plates were washed further and 50ul 
per well of the biotinylated detection antibody (Hyb 246-4 biotinylated anti-Human SP-
D antibody) added at 1:2000 in dilution buffer and then incubated for one hour at room 
temperature. Wash step was repeated, and 50ul of streptavidin-coupled Horse Radish 
Perioxidase at 1:5000 in dilution buffer was added. Wash step was repeated. The plates 
were developed with TMB microwell peroxidase substrate, and the reaction was 
stopped with 1M H3PO4. The plates were read at an absorbance of 450nm using a 
VersaMax microplate reader (Molecular Devices Corporation, Sunnyvale, CA, USA). 
2.5 Cell bank 
To optimise and construct the multi-colour flow cytometry panels, a stock of peripheral 
blood mononuclear cells (PBMCs) was created using buffy packs of blood obtained 
from the Western Province Blood Transfusion Service. Below is a visual representation 
of the workflow from collection through to experimentation (Figure 2.2). These buffy 
packs are ideal as they contain a high concentrate of cells from donors that are HIV 
negative. Two male and two female donors were utilised. 
 
Figure 2.2: Workflow for isolation, cryopreservation and analysis of peripheral blood 
mononuclear cells. Starting with the extraction of blood samples and storage at the western province 
blood bank, separation of mononuclear cells with ficoll gradient, cryopreservation, staining with 
fluorescently labelled conjugates to data collection and analysis via flow cytometry. 
2.5.1 Isolating PBMCs 
This isolation used Ficoll-Hypaque (Sigma Aldrich) for density gradient centrifugation 
to separate PBMCs from blood plasma, erythrocytes and granulocytes. After 
centrifugation, plasma and platelets are located at the top of the density gradient since 
they have a lower density compared to red blood cells, ficoll and PBMCs. The next 
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layer formed is the PBMC layer, which consists of lymphocytes and monocytes, and 
below the ficoll layer are the red blood cells with the greatest density. The Ficoll, Fetal 
Calf Serum (FCS) (heat-inactivated for 30min @ 60°C) and wash buffer (1% FCS HI 
in PBS) was equated at to room temperature. A large 50ml leucosep tube (Greiner Bio-
one) was used due to the quantity of blood in buffy packs. The tube consists of a filter 
disk, which allows for initial separation of blood and ficoll. 15ml of ficoll was added 
to 50ml leucosep tube and centrifuged for 1min at 2200g brakes on, forcing the ficoll 
below the leucosep gradient. The buffy pack or blood tube was mixed thoroughly before 
opening. For Buffy packs, 30ml was removed into cell culture flask, and 60ml PBS was 
added. Approximately 25ml of blood was then layered on top of the leucosep filter disk 
in each 50ml tubes and centrifuged for 18-22min at 2200g, brakes OFF to ensure the 
separation was not disturbed during centrifuge deceleration. The tubes were gently 
placed back into the rack, and opaque PBMC layer was identified. This layer was then 
harvested using a pipette being careful not to dip into the ficoll layer underneath which 
can affect cell survival. Donors were then pooled if centrifuged in separate falcon tubes. 
A top up with wash buffer and spin at 1500g for 10min (Wash 1 completed) was then 
performed. Only if a pellet had formed the supernatant was decanted. Wash buffer was 
topped up again, and the pellet was resuspended (Wash 2 completed) and centrifuged 
down again at 1500g for 10min. (*note buffy packs can house a lot of debris with 1-2 
more wash steps being beneficial in removing this excess) 
2.5.2 Cell count 
Approximately 10ul of sample per donor was removed and aliquoted into 96well plate 
(Nunc Maxisorp; Thermo Fisher Scientific). Then an equal quantity of trypan blue was 
added. 10ul of this sample was then pipetted into a haemocytometer and placed under 
the microscope at 40x magnification. The PBMC’s were counted in the top left and 
bottom right squares, being careful to dissociate them from red blood cells, with care 
taken not to count any dead cells identified by trypan blue. 
 
Sample concentration = Count x ml x 104  
 
The sample count was equated to an optimal freezing concentration of 20 x 106 cells. 
The cryovials containing sample did not exceed 1ml in volume.  
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2.5.3 Cryopreservation 
This procedure involves preserving cells at very low temperatures, in liquid nitrogen, 
to re-analyse samples at a later time with minimal damage. To ensure PBMC survival 
during freezing, the cells are resuspended with 10% DMSO in FCS. The Dimethyl 
Sulfoxide Freezing Media (DMSO) is a polar solvent that penetrates cell membranes 
without damage, protecting the cells from ice crystals that form whilst maintaining the 
integrity of cell membranes. Fetal calf serum (FCS) contains essential growth factors 
and proteins required for cellular survival. The required volume of freezing solution 
(10% DMSO in FCS) was made up and refrigerated (4°C) before use, as it is 
temperature-sensitive. The tubes were centrifuged down at 1000g for 5min and pellet 
resuspended with 10% DMSO in FCS (added dropwise) at an optimal concentration of 
20 x 106 cells. 500ul quantities of samples were aliquoted into freeze proof labelled 
cryovials. A Mr Frosty cryopreservation unit (Thermo Scientific) contains isopropanol 
and ensures slow step freezing of samples. Cryovials were placed in the Mr Frosty and 
into -80°C freezer for 24hours, ensuring slow step freezing of the PBMC’s at -1°C per 
minute. After step-freeze, they were transferred into a liquid nitrogen storage tank (-
192.2°C). 
2.5.4 Thawing   
Frozen PBMC samples were thawed by being placed in a 37°C water bath for 1-2 min 
until a tiny ice crystal remained. They were then transferred to FACS tubes and 
processed according to overnight incubation stage or direct staining protocols. 
2.6 Macrophage culture and growth 
This involved the preparation of monocytes and monocyte-derived macrophages for 
harvest and staining. Once PBMCs have been isolated (see 2.5.1) via density gradient 
centrifugation, with ficoll-hypaque, they are refrigerated and ready for the start of 
magnetic-activated cell sorting. To create isolated pools of monocytes and monocyte-
derived macrophages, the sorting is based on the presence of CD14. Cells are 
centrifuged and resuspended in cold MACS buffer at 1x107 cells and incubated for 
30min. Microbeads (specific for CD14) are added then another incubation for 30min. 
The sample is centrifuged at 500g for 5min and then resuspended in the buffer to 
prepare for magnetic isolation. The cell suspension is added to a LS column that has 
been rinsed with MACS buffer, unlabeled cells are collected in flow through, with 
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multiple washes. The column is then placed outside of the magnetic field in a tube and 
rinse to collect labelled cells. Cells are then counted and divided between cells to be 
cultured and cells that will directly go to FACS. Cells are resuspended in M-CSF at a 
final concentration of 20ng/ml and then plated out at 5x106 cells (10ml) in Petri dishes. 
At day three cultured cells are replenished with 5ml of M-CSF medium. At day seven 
cells are counted (MDMs are strongly adherent therefore they must be scraped from 
petri dish with cell scraper then transferred to falcon tubes before counting) and the 
sample removed for FACS control, the rest is centrifuged at 1000g for 5min and 
dissolved in complete medium (0.4x106) and stimuli is added to cells. The remaining 
cells are centrifuged at 1000g for 5min and dissolved in freezing medium recipe. For 
the final macrophage harvest and staining; cultured macrophages (isolated CD14+ 
PBMCs) that have been in GM-CSF for seven days, are removed from media (via 
scraping technique (see above), washed and then incubated with PBS & EDTA for 
10min (1ml 5uM EDTA in 50ml PBS) cells are then counted and stained for FACS. 
The stimulation of monocytes and macrophages in vitro was performed over 24hour 
period after culture and growth of the cells. GM-CSF media in addition to hatched 
larvae and/or rfhSP-D was added and incubated overnight.  
2.7 Flow cytometry 
2.7.1 Machine selection and mechanics  
The critical aspect of designing a multi-colour flow panel is to understand the various 
machines and their configurations that are available. Each flow cytometer retains a 
different internal setup with variations in bandpass filters and the number of lasers. The 
initial design revolved around an LSR II (BD Biosciences) with three lasers. During 
the optimisation, the panel was moved over to a Fortessa (BD Biosciences) (Figure 2.1) 




Figure 2.3: Fortessa flow cytometer configuration. Configuration of the Fortessa flow cytometer used 
for the largest portion of flow cytometric analysis. Another machine used was SATVI LSR II. (A) Filter 
configuration of Violet laser (405nm). (B) Filter configuration of Blue laser (455nm). (C) Filter 
configuration of Green laser (544nm). (A) Filter configuration of Red laser (633nm). Diagrams supplied 
by the South African Tuberculosis Vaccine Initiative (SATVI). 
2.7.2 Marker selection 
The markers present on specific cell types, both surface and intracellular, needs to be 
identified to obtain the correct anti-marker antibodies. Choosing the markers for 
monocyte panel was relatively straightforward with human subsets defined as classic, 
intermediate and non-classical subsets based on surface receptor repertoire of HLA-
DR, CD14 and CD16 [67] [174]. Recently genome-wide expression studies [175] have 
further sub-divided the intermediate monocytes into regions of increasing CD16. 
Defining the phenotypes of helminth infected and uninfected children in a rural setting 
would then involve CD14, CD16 and HLA-DR. Additionally, a lineage cocktail to gate 




lymphoid cells in human cohorts with infectious disease. Firstly Boyd et al. defined all 
ILCs as Lin-CD127+CD45+ and the expression of cKit (CD117), showing that 
exposure to microfilariae can attenuate ILC2 responses [176]. Most recently, Nausch 
et al. [177] performed a study on a rural cohort of children in Zimbabwe and created a 
simplified gating strategy, defining ILC2s as Lin-CD45+CD127+CD161+CD294+. 
This formed the basis for our choice of marker and fluorochrome combinations. When 
our research moved to Switzerland, adding a CD206 (Mannose receptor), which is 
present on macrophages.  
Table 2.1: Monocyte and macrophage antibody panel for flow cytometry 
 
Table 2.2: Type 2 Innate Lymphoid cell antibody panel for flow cytometry 
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2.7.3 Fluorochrome selection 
After markers of interest had been identified, the next step was to place them onto 
fluorochromes that would best suit their rarity. Generally, the brightest fluorochromes 
are placed onto the rarest of markers. Separation of significant populations also needs 
to be considered, which is best with a bright marker, although too much brightness can 
lead to unintended spill over into other channels. The final consideration is that not all 
markers are available commercially on all fluorochromes. The monocyte panel’s 
arrangement was adapted from our lab’s current human monocyte panel (Table 2.1) 
replaced with brighter and more accurate fluorochromes. On the ILC2 panel, there were 
three rare markers, which were updated with brighter options based on the Nausch et 
al. panel (Table 2.2).  
2.7.4 Assessing spectral overlap and bleed through  
The spectral overlap of fluorochromes was critical in determining how functional the 
panel became – too much spillover would lead to problematic compensation. Therefore 
it was in our best interest to choose markers that were situated with the largest gaps 
between peak emissions. This overlap was modelled on Biolegend’s Fluorescence 
Spectra Analyser available on their website (www.biolegend.com). This allowed us to 
view the emission and excitation of various antibodies selections and overlay them onto 
the flow cytometer setup by inputting laser lines and filters (Figure 2.1).  
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Figure 2.4: Spectral overlap of fluorochromes used to assess flow cytometry panels. Biolegend 
spectral viewer tool used to design the panels in best combination possible taking into account available 
fluorochrome-antibody combinations. Both panels exclude the viability marker, which emits as Amcyan. 
(A) ILC2 panel. (B) Monocyte panel. 
2.7.5 Surface staining  
Table 2.1 and 2.2 highlights a list of antibodies used in this protocol. Individual 
antibody titrations then determined the concentration at which antibodies were used—
staining approximately 1x106 cells per sample. The samples were stained in 96-well V-
bottom plates with 50μl antibody master mix (FACS buffer 2% FCS in PBS with 
optimised antibody dilution) for 45min in the refrigerator before the cells were washed 
twice in FACS buffer to remove excess unbound antibodies. The cells were 
resuspended in FACS buffer and read by a three laser Becton Dickinson LSR II 
machine and the data was collected DIVA© BD (San Diego, CA). FMO’s were used 




with GraphPad Prism software. Appropriate FACS compensation beads (BD 
bioscience) were used to compensate between the signal intensities of each 
fluorochrome to avoid spectral overlap. 
2.7.6 Viability marker 
The use of a viability marker to exclude cell death from the analysis is critical when it 
comes to using frozen down PBMCs. The inclusion of dead cells in marker specific 
gates could create false positives and increase non-specific background noise. 
2.7.7 Titrations 
Staining performed as per surface staining protocols listed above—titrations designed 
as single stain samples. Antibody volumes serially diluted from manufacturers 
recommendations (5ul per million cells for everything except lineage cocktail, 1ul per 
million cells) down to 1/8 of recommended volumes. No compensation required for 
single stain cell tubes. Optimal antibody concentration is calculated by measuring Mean 
Fluorescent Intensity (MFI) on cell populations positive for the antibody and measuring 
the MFI of the negative populations, which do not express the antibody. The positive 
MFI divided by the negative MFI gives the staining index or signal to noise ratio. These 
are compared over a titration series. A greater staining index is associated with better 
separation; however, over-straining can increase background noise. 
2.7.8 Fluorescence minus one (FMO) 
FMO’s performed as per surface staining protocols listed above. Designed to full stain 
cells of interest minus the antibody being tested. All antibodies required an individual 
FMO tube. Compensation performed using single stain compensation tubes and beads 
(for rare markers). Plotting the FMO channel versus all the other fluorochromes reveals 
any fluorescence spillover. To determine this experimentally, cells were stained with 
all antibodies in the panel, excluding the one of interest. This is performed for all 
antibodies in the panel. 
2.7.9 Preparation of compensation controls (cells and beads)  
For antibodies that were abundant and highly expressed on PBMC’s cell compensations 
were performed. For cell compensations a single stain tube created with the antibody 
of interest. No viability stain was added. For antibodies that were rare and ranged in the 
expression on PBMC’s bead compensations were performed. For bead compensations, 
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the isotype of the antibody was sourced from the manufacturer. According to isotype, 
either rat or mouse compensation beads were used (BD Biosciences). A single drop of 
beads was placed into a FACS tube, and the antibody of matching isotype was added. 
A single unstained tube per isotype was also made. These were then incubated in the 
dark for 10min. To that mix 500ul of PBS was added and the tubes were centrifuged at 
2100g for 3min. The supernatant was decanted, and the dead volume was resuspended 
to be analysed with flow cytometry. 
2.7.10 Flow cytometry 
Flow cytometry is a powerful technique that can be used to investigate immune 
responses. Characteristics of an individual cell can be identified within a cell 
suspension by detecting cell surface and intracellular markers [178]. It requires a 
specialised instrument, a flow cytometer, to measure the fluorescence of each cell 
[178]. The measurement is performed through specialised lasers that excite the 
fluorochrome-conjugated to the antibody that binds to the target of interest on the cell. 
The fluorochromes are excited at a particular wavelength and emit light at a longer 
wavelength. The filter system on the flow cytometer is designed with specific 
fluorochromes in mind to capture as little background noise as possible. In this context, 
flow cytometry can give us unique insight into the phenotypes of our cells of interest. 
2.7.11 Data acquisition and gating 
Samples were stored in the dark at 4°C after staining and acquired within 12hours of 
storage. Data was acquired on the LSRII (BD Biosciences) and Fortessa (BD 
Biosciences) with FACS Diva software. The number of events collected for samples 
ranged from 500,000 to 2,500,000. The analysis was performed using FlowJo version 





3 Systemic SP-D levels in humans with exposure to soil-
transmitted helminths 
3.1 Introduction  
SP-A and SP-D contribute significantly to control mouse-modelled nematode 
infections  (Thawer et al., Plos Pathogens [69]). This work has shown that infection 
with N. brasiliensis correlated with increased lung SP-D levels (Figure 1.6) and that 
administration of recombinant fragment human SP-D (rfhSP-D) protected against N. 
brasiliensis infection, as demonstrated by reduced worm burdens in rfhSP-D treated 
mice (Figure 1.7). This protection is associated with increased populations of type 2 
innate lymphoid cells (ILC2) and CD4+ T-cells (Figure 1.7). Subsequently, we 
hypothesised that SP-D could function as a novel anti-helminthic in human infections. 
In this chapter we investigate whether an association exists in humans between systemic 
levels of SP-D and previous or current exposure to 3 species of helminths endemic to 
South Africa; Ascaris lumbricoides, Trichuris trichuria and Toxocara spp. These soil-
transmitted helminths are not only crucial in the context of Southern Africa but also 
worldwide, causing unnecessary morbidity specifically in young children [35].  
Classified as a hydrophilic pulmonary collectin, SP-D plays a vital role in the 
modulation of mucosal immunity during exposure to microbes [134], mediating a range 
of infections [138], chronic non-communicable diseases [140] and allergy [139]. With 
the exact mechanism of interaction still to be identified, we postulate that the 
homeostasis of surfactant, as well as its homeostatic abilities, has a vital role in the 
physiology of disease. Damage to the epithelial layers during helminth infection 
initiates a type 2 immune cascade leading to the release of IL-25, IL-33 and TSLP, 
triggering downstream activation of effector cell populations that can promote helminth 
expulsion (Figure 1.4). As previously stated, during helminth infections involving 
parasites transiting the lung, the primary cell type releasing IL-33/IL-25 and priming 
anti-helminthic responses are alveolar type II cells (ATII cells) [133]. Further, a major 
immunomodulatory protein released by ATII cells is surfactant protein D (SP-D). 
Previous research conducted in our group demonstrated a critical role for SP-D in 
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controlling helminth infection in mice, the caveat being that the data is not directly 
relatable to human physiology. Here we translate these findings using human samples 
to determine whether an association exists between helminth exposure and SP-D.  
 
As stated in the introduction, an individual with an unusual IgE response is deemed 
‘sensitised’, and exposure to an allergen leads to diseases such as asthma, atopic 
dermatitis, allergic rhinitis and food allergy [79]. The type of allergic disease presents 
as different pathophysiology depending on the affected area. During both allergic 
disease and helminth infection, the severity of the disease is mediated in part by the 
balance of specific IgE and IgG4. In the context of allergies, high levels of allergen-
specific IgE is phenotypically associated with a heightened state of allergic disease, but 
when the balance shifts toward allergen-specific IgG4 it enters a more controlled form 
of allergic disease. Allergen-specific IgE binds to effector immune cells such as 
eosinophils and mast cells that activate effector mechanisms at barriers (i.e. lung) and 
generate allergic responses. The entry of allergic disease into a controlled stage is 
associated with an increase in allergen-specific IgG4; the IgG4 inhibits IgE function by 
competitively binding to an allergen and, due to its negligible functionality, mediates 
inflammatory response. In the context of helminth infection, high levels of antigen-
specific IgE is related to current acute infection or natural resistance. In contrast, 
elevated levels of antigen-specific IgG4 is associated with an asymptomatic or chronic 
state of infection [158].  
 
We postulate here that when a helminth infects a patient with atopy (in particular lung-
based infection), the disease outcome will be altered in comparison to a non-allergic 
person based on the balance of specific IgE and IgG4 being altered. This may involve 
the helminth infection exploiting the mechanism of allergic disease, pushing towards 
the production of IgG4 (driven through IL-10 production), which creates a 
microenvironment for the helminth to live with negligible inflammation, or in an 
asymptomatic state.  
 
This chapter uses two separate cohorts:  
1) Masiphumelele, Cape Town surrounds. Samples were acquired in collaboration with 
Associate Professor Jo-Anne Passmore (UCT) (Protocol number 258/2006).  
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2) An Allergy Foundation, South Africa cohort, recruited by Prof. Mike Levin. This 
second cohort comes from an umbrella epidemiological study known as the South 
African food sensitisation and food allergy (SAFFA) study. Whereby allergy 
prevalence was assessed in urban and rural children by screening for food allergy, 
aeroallergens and companion epidemiological data. SOSALL is a case-control sub-
study focusing on mechanistic, which aims to review helminth infection, and 
sensitisation in rural and urban Xhosa children with or without atopic dermatitis, by 
using 220 age-matched rural and urban children using stool and serum samples. 
 
 
Referring back to aims and objectives, our aim for this section is to identify whether 
the key markers of protection identified in our mouse study are also found in human 
samples. We hypothesise that there would be an overlap in the immunological effect 
between mouse and human protective immunity to helminth infections. We also look 
at the atopic status and review whether there is any influence on SP-D or helminth 
infection. Our objectives are as follows; (1) Does exposure to helminth infection alter 
serum levels of SP-D in humans (2) If alteration does happen, are there any correlates 
of protection/exposure that exist in human serum that indicates how helminth infections 
navigate human immunity and how SP-D operates around this. (3) Do we see any 
correlation between levels of atopy and SP-D in atopic cases and controls (4) Does 
helminth infection prevalence influence atopy?   
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3.2 Results 
3.2.1 The Masiphumelele cohort: The association between helminth-specific 
immunoglobulins and SP-D is limited to antigen-specific IgG4 
To establish if any relationship existed between raised detection of Ascaris-specific IgE 
or IgG4 and systemic amounts of SP-D, we carried out western blot detection (see 
materials and methods) of SP-D in serum samples that were already established to be 
either Ascaris-specific IgE or IgG4 positive or negative. Ascaris-specific IgE 
(CAPRAST) or Ascaris-specific IgG4 (ELISA) was also established. The samples were 
stratified as positive or negative for immunoglobulin titre (Ascaris-specific IgG4 or 
Ascaris-specific IgE), with 7 IgG4 positive and 7 IgG4 negatives, 7 IgE positive and 7 
IgE negative samples (Figure 3.1). There were no differences in SP-D levels between 
samples positive and negative for IgE (Figure 3.1 A). In contrast, in samples positive 
for IgG4 we found a significant difference (*p=0.026) in SP-D titer, as compared to 
their controls (Figure 3.1 B). This figure illustrates that, in humans, there is a positive 
association between Ascaris-specific IgG4 and levels of surfactant protein D, an 
association that is as of yet, undescribed.  
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Figure 3.1: SP-D is positively associated with IgG4 levels. Serum samples with known Ascaris-
specific IgG4 (quantified using ELISA) and IgE (quantified using CAPRAST) titres were tested for SPD 
by Western blot. Samples were stratified into (A) Women either positive (n=7) or negative (n=7) for 
Ascaris-specific IgE or (B) women either positive (n=7) or negative (n=7) for Ascaris-specific IgG4. The 
SP-D as the monomer is a 43kD band on the western blot. Significance was assessed using Mann-
Whitney unpaired T-test. 
 
3.2.2 Basic epidemiology of the SOSALL cohort  
The SOSALL study is a follow-on of the SAFFA study (figure 2.1 in methodology). 
SOSALL aims to review allergic sensitisation in rural and urban Xhosa children with 
or without atopic dermatitis and the factors that may influence this sensitisation, 
including helminth infections. In total, 220 participants were recruited from the pool of 
SAFFA participants, with stool available from 158 and serum available from 129. The 
cohort epidemiological factors age, weight, height, antibiotic, asthma, allergic rhinitis 
(hay fever), dog owner, cat owner, combined ownership are described in Table 3.1. It 
is important to note that data collection was done verbally via survey and consultation 







































































































































































responses. For example, some participants reported no allergy or eczema but tested 
positive (SCORAD) for eczema.  
Table 3.1: Epidemiological data in the SOSALL cohort grouped based on geography and atopy. 
 
 
3.2.3 Urban AD negative children showed increased total IgG and IgG4 in the 
SOSALL cohort 
In order to establish whether the positive correlation between helminth-specific 
antibody and SP-D is seen in a larger sample pool, we carried out a new set of ELISAs 
using samples from the SOSALL cohort. Baseline levels of the immunoglobulins total 
IgG, and total IgG4 were quantified. Samples detected above a specific value were 
deemed positive and quantified using arbitrary units based on endpoint titration ELISA. 
Results in this study were stratified into urban and rural components as well as the 
presence of atopic dermatitis (case)(AD+) or absence (control)(AD-). The criteria for 
selection of allergic cases were moderate to severe atopic dermatitis as determined by 
consultation with a medical professional and SCORAD analysis.  
 
When grouped based on geographical location, total IgG was significantly 
(***p=0.0001) raised in urban participants (Figure 3.2 C) with that effect being a result 
specifically of total IgG in the urban control group being raised (**p=0.0071) (Figure 
3.2 A); this is compared to urban case group as well as both rural groups. We also found 
the same trend in the urban population with total IgG4 significantly raised (*p=0.012) 
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(Figure 3.2 F), and again it was with that effect being anchored specifically by total 
IgG4 in the urban control group, which was raised (**p=0.007) (Figure 3.2 D). This 
may indicate differences in immune development or activation between rural and urban 




Figure 3.2: Total IgG and IgG4 titers were raised in urban AD- controls compared to rural and 
AD+ cases. Antibody levels from n=151 samples were measured by ELISA and stratified by the 
following ways: (A) Total IgG (n=131 samples above detection limit) (B) Total IgG case vs control (C) 
Total IgG rural vs urban (D) Total IgG4 (n=30 samples above detection limit) (E) Total IgG4 case vs 
control (F) Total IgG4 rural vs urban. Antibody titres are presented as log-transformed arbitrary units. 
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3.2.4 Antigen-specific IgG4 was widespread in the SOSALL cohort. Rural AD+ 
participants showed increased Ascaris-specific IgG4  
To establish whether the participants have previously been or were currently infected 
by specific helminth species, we quantified a known marker of helminth exposure. We 
tested for immunoglobulins from 3 soil-transmitted helminth species; Ascaris 
lumbricoides, Trichuris trichuria and Toxocara species (various). We used antigen-
specific IgG4 as a marker of exposure [81] [157]. This is an immunoglobulin known to 
be produced in response to long term (chronic) or historical infection and is the rarest 
antibody subtype, indicating whether the individual has ever been previously exposed 
to the parasite, not just if there is a current infection (which would be characterised by 
the presence of IgE) [157]	[179]. Ascaris (Figure 3.3 A), Trichuris (Figure 3.3 D) and 
Toxocara (Figure 3.3 G) show samples above cut off value stratified based on 
geographical location and atopy (AD+ or AD-). Ascaris (Figure 3.3 B), Trichuris 
(Figure 3.3 E) and Toxocara (Figure 3.3 H) show samples stratified based on atopy 
only (AD+ or AD-). Ascaris (Figure 3.3 C), Trichuris (Figure 3.3 F) and Toxocara 
(Figure 3.3 I) show samples stratified based on geographical location only.   
 
The prevalence of helminth infection in our cohort was summarised in Table 3.2. 
CAPRAST detection of anti-Ascaris lumbricoides IgE detected low numbers of 
positive samples, indicative of low levels of acute or current exposure (data not shown). 
Both Ascaris lumbricoides and Toxocara spp antigen-specific IgG4 were detected in 
over 25% of study participants and Trichuris trichuria in 20% of participants, 
suggesting a high rate of previous long-term exposure to the parasites (Table 3.2). There 
is a discrepancy between the antigen-specific IgG4 and total IgG4 in our cohort. Despite 
having relatively large amounts of detectable antigen-specific IgG4, if we compare this 
to total IgG4, there are a lot fewer positive samples.  
 
The detectable level of Ascaris-specific IgG4 in rural AD+ children was significantly 
increased (Figure 3.3). We also found significantly more Ascaris-specific IgG4 in rural 
participants overall (**p=0.0043) (Figure 3.3 C). We found significantly more Ascaris-
specific IgG4 in AD+ participants (**p=0.003) (Figure 3.3 B). These trends are a result 
of significantly increased Ascaris-specific IgG4 in rural AD+ children seeing that 
detection of Ascaris-IgG4 in rural cases was significantly raised compared to the 
control group (**p=0.001) (Figure 3.3 A).  
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Table 3.2: Prevalence of previous helminth infection in the cohort based on the presence of parasite-
specific IgG4 
URBAN (Cape Town) 
 
Cases (AD+) Controls (AD-) 
Ascaris lumbricoides 15% (n=20) 15% (n=40) 
Trichuris trichuria 20% (n= 20) 25% (n= 40) 
Toxocara spp  25% (n=20) 25% (n=40) 
RURAL (Eastern Cape) 
Ascaris lumbricoides 53.8% (n=39) 20% (n=40) 
Trichuris trichuria 23% (n=39) 12.5% (n=40) 
Toxocara spp  30.7% (n=39) 30% (n=40) 
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Figure 3.3: Ascaris-specific IgG4 titers were raised in rural cases compared to Urban cases and 
rural controls. Serum antigen-specific IgG4 titers from n = 151 samples were analysed by ELISA and 
stratified by the following ways: (A) Ascaris-specific IgG4 (n=38 samples above detection limit) (B) 
Ascaris-specific IgG4 case vs control (C) Ascaris-specific IgG4 rural vs urban (D) Trichuris-specific 
IgG4 (n=27 samples above detection limit) (E) Trichuris-specific IgG4 case vs control (F) Trichuris-
specific IgG4 case vs control (G) Toxocara-specific IgG4 (n=38 samples above detection limit) (H) 
Toxocara-specific IgG4 case vs control (I) Toxocara-specific IgG4 case vs control. Antibody titres are 
presented as log-transformed arbitrary units. Overall significance assessed using the Kruskal-Wallis test. 
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3.2.5 SP-D associated with helminth species that transit the lung stage as part 
of their lifecycles 
To confirm the association we observed in the Masiphumelele cohort between SP-D 
and helminth specific IgG4 (Figure 3.1), and to assess whether this association is 
present in the SOSALL cohort, we compared the immunoglobulins present (Total IgG, 
total IgG4, helminth specific IgG4) with the samples’ corresponding serum SP-D 
levels. SP-D was quantified using ELISA. 
 
As was found in the first cohort, these results show that Ascaris-specific IgG4 was 
associated with raised levels of circulating SP-D (*p=0.02) (Figure 3.4 C). Toxocara-
specific IgG4 also positively associated with raised levels of circulating SP-D 
(*p=0.0138) (Figure 3.4 D). In contrast, there was no association between Trichuris 
spp IgG4 and SP-D (p=0.76) (Figure 3.4 E). No association was found between show 
total IgG or IgG4 and SP-D, respectively (Figure 3.4 A and B). All associations were 
assessed using the spearmen correlation. The sample group size was n = 37 (Ascaris) 
and n = 38 (Toxocara), which is substantially larger than in the Masiphumelele cohort 
(n=7). 
 
Ascaris lumbricoides is a common roundworm whose lifecycle involves a multi-organ 
migration through the host, including a vital lung stage that creates specific pathology. 
Larval migration, through direct mechanical force, causes substantial pulmonary 
damage with type 2 pathology resembling allergic airway disease (Figure 1.3) [38]. 
Trichuris trichuria is a common whipworm whose lifecycle is confined to the 
intestines, colonising the gut epithelium by epithelial tunnelling, but not totally 
exposing the mucus layer (Figure 1.3). Toxocara species (various) are common 
roundworms that when infecting humans create dead-end hosts; the lifecycle can cause 
serious pathology and exposure via companion animals either, domestic or livestock is 
common (Figure 1.3) [38]. We postulate that due to the variation of lifecycles between 
Ascaris lumbricoides and Trichuris trichuria, certain helminth infections have a greater 
effect on serum SP-D levels than others. In the case of both Ascaris and Toxocara, their 
lifecycles have stages that involve specific migration through the lung. As ATII cells 
in the lung are the chief source of SP-D, it stands to reason that these helminth species 
directly affect the production of this protein. They cause damage to the epithelial lining 
of the lung, just as asthma also causes epithelial damage, which leads to a release of 
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SP-D in the serum. We see the same effect here with helminth induced epithelial 




Figure 3.4: SP-D is positively associated with Ascaris and Toxocara but not Trichuris-specific IgG4 
levels. Serum SP-D was quantified using ELISA and stratified by the following ways: (A) Total serum 
IgG (n=37) assessed against serum SP-D. (B) Total serum IgG4 (n=37) against serum SP-D. (C) Ascaris-
specific IgG4 (n=37) against serum SP-D concentration. (D) Toxocara-specific IgG4 against serum SP-
D (n=38). (E) Trichuris-specific IgG4 against serum SP-D (n=38). Antibody titres against helminth 
antigens are presented as arbitrary values—significance established by Spearman correlation. 
3.2.6 Serum SP-D is not an indicator for atopic dermatitis or geographical 
location in SOSALL cohort  
We assessed serum SP-D in the SOSALL cohort to establish whether geographical 
location or atopy had any effect on serum titers since SP-D is associated with protection 
from allergy and immunity to helminth infection	[69] [149]	[136]. SP-D was quantified 
using ELISA. We used a standardised control and to ensure as little experimental 
variation as possible, and this control was run on each plate at the same time using the 
same reagent sets for each set of samples. As with total immunoglobulin and antigen-
specific data, we grouped the SP-D data according to their geographic and atopic 
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measures (Figure 3.5). No clear association was apparent between groups with similar 
medians across geography and atopy. However, rural AD+ participants showed 
marginally lower SP-D titers compared to rural controls, although this was not 
significant. This trend would perhaps this trend would become more apparent if the 
cohort size was increased. We also found large variations in cohort participant’s serum 
SP-D levels. Most measured between 1ng/ml and 30ng/ml but some outliers measured 
as high as 1000ng/ml. SP-D can be present systemically and at mucosal layers in 
relatively large amounts; the reason for the outliers could be related to a number of 
reasons, including disease affecting the lung or other systemic conditions [141]. 
	
Figure 3.5: Surfactant protein D titers did not associate with atopic dermatitis or geographical 
location. Serum SP-D from n = 151 samples was quantified using ELISA and stratified by the following 
ways: (A) All cohort samples stratified based on location and allergic status (B) Samples compared based 
on case (AD+) or control (AD-) status. (C) Samples compared based on location. Significance assessed 
using the Kruskal-Wallis and Mann-Whitney test. 
3.2.7 SP-D was not an indicator for the severity of atopic dermatitis  
We also evaluated to what extent SP-D may play a role in allergic dermatitis. In the 
cohort overall, or split based on geography, we did not see any association between the 
severity of AD and serum SP-D levels. This means SP-D was not an indicator of the 
severity of atopic dermatitis. This was measured by assessing the atopic dermatitis 
positive children’s SCORAD scores compared to serum SP-D. SCORAD (SCORing 
Atopic Dermatitis) is a standard test used to assess the severity of atopic dermatitis as 
objectively as possible; the scale runs from 0-100 based on various metrics including 
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understanding the individual severity of atopic dermatitis and can be directly compared 
to SP-D to assess for any associations.  As with total immunoglobulin and antigen-
specific data, we grouped the SP-D data according to their geographic and atopic 
measures (Figure 3.5). SP-D concentration is reviewed against measured against all 
atopic dermatitis positive children in cohort regardless of geographical region (Figure 
3.6 A), in the rural specific cohort (Figure 3.6 B), and against urban cohort (Figure 3.6 
C). The SCORAD scores are also compared between rural and urban (Figure 3.6 D).  
 
	
Figure 3.6: There was no association between participant’s serum surfactant protein D and 
SCORAD scores.	(A) All atopic dermatitis positive children’s SCORAD scores against serum SP-D 
(ng/ml). (B) Rural atopic dermatitis positive children’s SCORAD scores against serum SP-D (ng/ml). 
(C) Urban atopic dermatitis positive children’s SCORAD scores against serum SP-D (ng/ml). 
Significance for all association curves was established by Spearman correlation. (D) Samples SCORAD 
scores compared based on geographical location. Significance assessed using Mann-Whitney test. 
3.2.8 Participants with atopy have unusually high levels of Ascaris sensitisation 
but not active infection 
These results have not been generated by this dissertation but still originate from the 
same study and pertain to the overall findings. Previous SOSALL Stool analysis (Kato-
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generated by collaborators) in the SOSALL cohort; this data was compared to 
participants that had been sensitised to Ascaris (cleared or chronic infection, measured 
by Ascaris-specific IgE levels) based on whether they had atopic dermatitis or not. 
 
Non atopic (AD-) control children had 6.7% (n=45) urban and 10.5% (n=41) rural 
kato-katz positive (active infection) stools; atopic (AD+) children showed no evidence 
of active infection (both urban and rural were 0%) (Table 3.3). The non-atopic controls 
also showed Ascaris sensitisation (Ascaris IgE >0.35kU/L) with 5.1% urban (n=39) 
and 9.7% rural (n=31) (Table 3.3). Despite no evidence of active infection both urban 
and rural case participants with atopy had high levels of Ascaris sensitisation, 21.4% 
(n=28) and 9.7% (n=31) respectively (Table 3.3).  
 
As atopic participants had no active infection but were still sensitised to Ascaris (at 
higher rates than AD- controls for the urban group), this raises an interesting question: 
Are atopic children clearing active infection better than their non-atopic counterparts?  
Table 3.3: Rates of active infection and Ascaris sensitisation in SOSALL cohort 
URBAN (Cape Town) 
 
Cases (AD+) Controls (AD-) 
KatoKatz Positive 0% (n=37) 6.7% (n=45) 
Ascaris IgE >0.35kU/L 21.4% (n=28) 5.1% (n=39) 
RURAL (Eastern Cape) 
KatoKatz Positive 0% (n=38) 10.5% (n=41) 
Ascaris IgE >0.35kU/L 9.7% (n=31) 9.7% (n=31) 
	
3.2.9 SAFFA cohort: Food allergy or sensitisation is lowered in the rural cohort 
(Data generated by collaborators)   
The following results originate from the umbrella epidemiological SAFFA study of the 
SOSALL cohort analysed above. It has previously been established that infants with 
early-life food allergy are predisposed to show markers of atopy [180]. The SAFFA 
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study, reviewed how common food allergy is in Southern Africa, screening 1200 urban 
children (Cape Town, Western Cape) and 400 rural children (Mqanduli, Eastern Cape), 
all were healthy and between the ages of 12-36 months. All children were screened for 
food allergy by performing skin prick tests for the seven most common food allergens 
(egg white, peanut, cows’ milk, fish soy, wheat and tree nuts), and parents completed a 
questionnaire that detailed weaning, family history, environmental conditions and 
dietary exposures.  
 
Their findings demonstrated that 2.5% of 12-36 month aged children in Cape Town had 
a challenge confirmed food allergy, mostly to egg (1.9%), peanut (0.8%) and milk or 
fish (0.1%) [181]. Urban sensitization to any food was 11.4% (SPT response > 1mm) 
and 9.0% (an SPT response > 3 mm). Sensitization in rural cohorts was significantly 
lower than in the urban cohort with 4.5% (SPT response > 1mm) and 2.8% (SPT 
response > 3mm) [181]. The urban rates of food allergy (Cape Town) match that of 
middle-income countries, but the significantly lowered rate of food allergy in rural 
South African children suggests that rural-urban differences could be a more important 
factor than ethnicity and genetic determinants in the development of food allergy and 
potentially other allergies. The urban cohort was significantly more likely to have 
familial history of allergic disease (48.8% vs 7.5%, p = 0.001) and reported a higher 
prevalence of comorbid eczema (23.5vss. 1.8%) and allergic rhinitis (23.5% vvs3.3%) 
in comparison to the rural cohort [181]. The urban cohort was significantly more likely 
to have familial history of allergic disease (48.8% vsvs.5%, p = 0.001) and reported a 
higher prevalence of comorbid eczema (23.5% vs 1.8%) and allergic rhinitis (23.5% vs 
3.3%) in comparison to the rural cohort [181]. In total,11.7% of the urban cohort had 
clinical signs of atopic dermatitis (AD), and 8.5% had signs of allergic rhinitis (AR). 
In the rural cohort AD and AR were significantly less frequent (0.8% and 0.0%). The 
urban food allergy rates did not differ between ethnicities; the urban cohort sampled 
black African, mixed ancestry and Caucasian.  
 
3.3 Discussion  
In this chapter, we examined three key immune components that could influence each 
other. Firstly, we reviewed helminth infection rates and its influence on SP-D levels. 
We then analysed the influence SP-D has on the atopic disease prevalence in our cohort, 
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and we examined the relationship between the atopic disease and helminth infection 
rates. We studied the system as a whole, taking into account helminth infection, SP-D 
influence and atopic disease together to potentially gain a broader insight into how these 
components work together in combination to influence human immune responses.  
3.3.1 Surfactant protein D and helminths 
Research performed by Thawer et al. in our laboratory revealed the connection between 
SP-D and helminth infections [69].  That study presented evidence that SP-D interacts 
with the helminth itself, (Figure 1.7) providing protection against helminth invasion 
(Figure 1.6) and leaving a long-term effect on murine immunology. Here we 
investigated whether this connection existed in human samples by assessing markers of 
helminth infection and their corresponding changes in serum concentration levels of 
SP-D. In agreement with the Thawer et al. study, our findings showed an association 
in 2 different cohorts between helminth specific IgG4 and surfactant protein D.  
 
Helminth specific-IgG4 is related to SP-D. We compared children with known 
helminth exposure from the small Masiphumelele cohort to assess serum SP-D. 
Results indicated that SP-D levels positively associated with the development of 
antigen-specific IgG4, but not to the development of antigen-specific IgE. In the 
introduction, it was described how there are defined roles for both IgG4 and IgE in 
immune activation. Traditionally, in helminth infections, a short acute infection induces 
production of IgE, while longer more chronic or resolved infections develop an IgG4 
response [158]	[81]. Development of later stage immunoglobulins like IgG4 suggests a 
mediation of infection; our data illustrates that this mediation is associated with 
increased serum concentration of SP-D. This mediation not only indicates longevity of 
infection but potentially a shift to a less aggressive inflammatory phenotype. Over time, 
some parasitic infections down-regulate the hosts type 2 inflammatory immune 
response [46] towards both helminth antigen and non-related antigens [44]. This form 
of immune evasion explains the success of parasite invasion in tightly regulated 
immune environments such as the mucosa.  
 
In the context of the helminth, since we have found that levels of SP-D are elevated in 
humans and it has been shown to be modulated by the helminth in murine studies, we 
can hypothesise that similar regulatory mechanisms could be employed for long term 
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survival in the host. The Thawer paper has functional data supporting some of these 
claims with SP-D-/- mice having a profound impairment of innate host immunity and 
the ability to resolve the infection, raising pulmonary SP-D levels prior to infection 
enhanced parasite expulsion and type 2 immune responses, including increased 
numbers of IL-13 producing type 2 innate lymphoid cells (ILC2), elevated expression 
of markers of alternative activation by alveolar macrophages (alvM) and increased 
production of the type 2 cytokines IL-4 and IL-13.	It is likely that SP-D could interact 
not only with the parasite directly but also potentially with immune cells that may lead 
to a highly specific immune activation state in sensitive tissues such as the human 
mucosa.  
 
SP-D and helminth association occurs specifically in helminth species that transit 
the lung in their lifecycles. Next, we analysed the case-control SOSALL cohort that 
originated out of the larger SAFFA umbrella study. Our analysis reviewed helminth 
specific markers of infection (IgG, IgG4 and IgE) and surfactant protein D. As we 
observed in cohort 1, Ascaris-specific IgG4 is associated with SP-D. Out of three 
helminth species tested, only two tested positive for this association (Ascaris and 
Toxocara); we hypothesise that apparent differences between helminths and their 
lifecycles underlies this finding. Ascaris and Toxocara [39] species lifecycles are 
systemic – specifically, their lifecycle involves a lung stage, and with the lung being 
the largest producer of SP-D [130], it would be logical to assume they come into contact 
with a large amount of SP-D protein and its producer, ATII cells. On the contrary, the 
Trichuris lifecycle, which did not correlate with increased SP-D, is localised to the gut, 
specifically limited to epithelial burrowing. Based on these findings, this may suggest 
that only helminth species (such as Ascaris spp and Toxocara spp), which transit the 
lung and other mucosal barriers as part of their life cycle, induce an associated increase 
in serum SP-D. 
 
We might be seeing a mechanism by which low-grade helminth infection makes use of 
the body’s own regulatory mechanism to defend against inflammation. The evidence in 
this dissertation (SP-D is associated with increased specific-IgG4) for the upregulation 
or increased concentration of serum SP-D during low-grade chronic inflammatory state 
could point towards it being part of the unique mechanism of helminth survival. 
Research shows helminth survival strategies are driven by their co-evolution alongside 
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humans, and helminths can turn hosts into carriers or sub-clinical patients [112] [113]. 
This happens through the specific regulation of chronic low-grade inflammation with 
the mechanism involving activation of TLR2 by regulatory DCs [65]. Interestingly, 
another molecule that activates TLR2 is SP-D [182]. SP-D also binds to IgG, IgM, IgA, 
IgE, in a calcium-dependent manner [51], specifically recognising both Fc and Fab 
domains of IgG [147]. The results of this study could be demonstrating an SP-D 
mediated amplification of IgG responses through enhancement mechanisms of immune 
aggregation and phagocytosis. The evidence we see for the upregulation or increased 
concentration of serum SP-D during low-grade chronic inflammatory state could point 
towards it being part of the unique mechanism of helminth survival. The interplay 
between a systemic helminth infection such as Ascaris and the long-term immune 
response could be reliant on homeostatic molecules like SP-D, which has both 
suppressive and activated states in human mucosa. This section answers objective one 
showing that exposure to an STH changes serum concentration and objective 2 showing 
a potential correlate of exposure that exists in human serum. 
3.3.2 Surfactant protein D and allergic disease 
Surfactant protein D has been implicated in various respiratory diseases, including 
allergic asthma [150] [183] [156], being both a biomarker of disease severity as well as 
being involved in pathophysiology. The abnormal modification of the pulmonary 
environment leads to the breakdown and modification of SP-D and its homeostatic 
capabilities in the lung [132]	 [146]. The detectable level of serum SP-D in allergic 
asthma has been shown to be significantly higher than non-allergic patients, and we 
know SP-D directly binds to and opsonises allergens. Our cohort investigated atopic 
dermatitis, a different allergic disease, that is not present in the lung but presents itself 
on the skin [184]. Therefore we investigated whether SP-D could have any associations 
with another allergic disease that is in a remote location from the source of the protein, 
concluding that SP-D titer does not indicate the severity of atopic dermatitis.  
 
We quantified SP-D titers in the SOSALL cohort and stratified them by geographical 
location and AD status. There were large variations in participant’s serum SP-D levels, 
which is expected as the serum SP-D levels from person to person has been shown to 
be highly variable. By comparing SP-D and SCORAD scores, we assessed the 
association between serum SP-D and the severity of AD. The rural AD+ SCORAD 
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scores trended towards being raised compared to urban AD+ children, but not 
significantly. We determined that neither SP-D serum titers nor SCORAD scores show 
any association to atopy or geographical location, and we, therefore, concluded that SP-
D does not indicate the severity of atopic dermatitis. Other research shows that allergic 
disease may be a factor in how much serum SP-D is present in a patient and that it is a 
reliable indicator for the severity of the disease, but these studies are specific to allergic 
diseases affecting the lungs, such as asthma and rhinitis [185]. Our research points to 
SP-D not being an indicator of the severity of atopic dermatitis. However, in rural cases, 
in particular, SP-D concentration is slightly lowered compared to the control group, and 
SCORAD scores are slightly increased. There may be subtle immunological 
mechanisms at play here that the relatively crude measure of serum SP-D cannot pick 
up. For protein targets abundant in biological sample alternative measures of SP-D will 
be useful alongside the ELISA in order to fortify the findings surrounding SP-D 
concentration. This section answers objective three showing that atopy, specifically 
atopic dermatitis, has no influence on serum SP-D. Even though SP-D is a biomarker 
for severity of allergic asthma, it is not a biomarker for atopic dermatitis and the trends 
surrounding atopy, and geographical location is too loose to pin down.  
3.3.3 Helminths and allergic disease 
This section assessed whether participants with allergic disease have altered response 
to helminth infection and whether helminth infection alters the phenotype of allergic 
disease. Helminths are widespread [186], and the SOSALL cohort was drawn from 
rural and urban settings in South Africa; therefore, we tested for parasites endemic to 
the area [186]. As previously stated, helminth infections are loosely associated with a 
reduction in risk of allergy or allergic disease [113]. The hygiene hypothesis or old 
friends hypothesis dictates that organisms with which we co-evolved have developed 
unique survival strategies for preservation that as a byproduct downregulates or 
desensitises human immunity [103, 104]	 [105]. If through the development of 
immunity early on in life, we do not receive specific stimuli, our likelihood of 
developing a hypersensitivity response (allergy) is increased. In developing nations, in 
particular, an increase in affluence and environmental conditions come with decreased 
risk of parasitic infection. This developmental phenomenon could be a reason for 
increased immune-mediated diseases like allergies [187, 188]. In developing nations, 
considerations need to be made over socio-economic factors, such as the likelihood of 
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a more affluent home to respond to an ailment of their child, the access to healthcare 
systems both geographically and financially, cultural implications of belief systems and 
trust in ‘western medicine’.  
 
We assessed the trends between the rates of allergy in our cohort and the levels of 
helminth infection. During helminth infection, immune responses and hyper-reactivity 
are mediated by a balance of parasite-specific IgE and IgG4. After the initial response 
of IgE, which is acute and powerfully inflammatory, the development of IgG4 occurs. 
There is a balance between these specific antibodies, with IgG4, through various 
mechanisms, down-regulating inflammation and balancing tightly regulated immune 
areas. We postulate that the balance of immunoglobulins IgE and IgG4 during helminth 
infection and allergy could have a role in determining long term infection status and 
hypersensitivity reactions. 
 
Upon review of the epidemiological data, we saw lowered rates of asthma and allergic 
rhinitis in rural AD- group. This is to be expected, due to the similarity of underlying 
mechanisms of allergy and if you already have an allergic disease, the likelihood of 
developing other allergic disease is increased [189] [190]	[191]. Dog or cat ownership 
was also significantly higher in the rural cohort for both allergic and control children. 
This is important in the context of helminth infections being soil-transmitted through 
contaminated faeces, ownership of an animal that lives in close proximity to a child 
would mean exposure to a larger array of both pathogens and allergens. In accordance 
with research, both the “hygiene hypothesis” and “old friends hypothesis”, microbial 
exposure across the board could influence the development of immunity in young 
children [103, 104]	[105].  
 
Urban AD- children have increased proportions of total IgG and IgG4 in serum. The 
increased proportions of total IgG and IgG4 in serum could indicate that the rural-urban 
divide plays a significant role in the development of immune response, with urban 
children producing more IgG, in response to exposure to allergens and microbes.  
 
Rural AD+ participants have increased proportions of Ascaris-specific IgG4. Atopy 
can lead to a defective skin barrier as the first line of defence to pathogens, which could 
explain the higher rate and magnitude of infection [192]. In children, due to the nature 
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of the allergic disease, with consistent itching and scratching, atopic dermatitis 
increases the hand to skin/mouth contact [184], increasing likelihood of transmission 
of disease. In rural areas particularly, the chance of children being exposed to helminths 
at a young age is high, even though there are active anti-helminthic programs in place 
to combat this. Interestingly, the trends were only apparent with Ascaris, perhaps due 
to being the most widespread of the three species we tested for.  
 
Atopic participants have high levels of Ascaris sensitisation. Data collected before this 
dissertation showed differences in the current helminth infection rates of AD+ children 
and AD- children across the rural/urban divide [181]. AD+ participants have no 
evidence of active infection with Ascaris but have all been sensitised to helminth 
antigen (seen in specific IgE titer). The ability of the AD+ cases to quickly clear active 
infection is undefined, but it is known that allergy up-regulates Th2 responses, which 
in turn has knock-on immune effects, i.e. B-cell upregulation and increased antibody 
production [193]. As atopic participants had no active infection but were still sensitised 
to Ascaris (at higher rates than AD- controls for the urban group), this raises an 
interesting question: Are atopic children clearing active infection better than their non-
atopic counterparts? A child with allergic disease would have up-regulated Th2 and 
therefore, upon infection with helminth, clear it more efficiently due to increased 
immune activation. In the non-atopic, low-grade infestation continues 
asymptomatically with no large Th2 response due to the modulatory abilities of 
helminth itself [114] [14] [177].  
 
Immune responses are dependent upon received stimulation, whether that is in the form 
of pathogen or allergen. Another critical consideration is the timing in which the 
stimulus is received. Whether a helminth infects during a stage of heightened allergic 
disease (high IgE) or controlled allergy (high IgG4) [158] [157], the level of Th2, the 
age of the patient and their ability to form a response; all influence variation regarding 
the level of Th2 activation inflammatory profiles. Our data showed rural AD+ children 
had increased titers of serum Ascaris-specific IgG4. We argue that the susceptibility of 
a child in an area with a high prevalence of Ascaris is increased, as is the weakened 
barrier integrity and subsequent helminth entry point. We review children that have an 
allergic disease and helminth infection, perhaps the increased IgG4 titers in these rural 
children could be piggybacking off the same mechanism, that allergic response and 
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helminth infection make use of the inhibitory effect of IgG4. We do not have data to 
the time of year and corresponding season that data was gathered, which could 
influence what allergic state they are currently in.  
 
Relating the up-regulation of Th2 to balance of IgG4 and IgE in helminth infections 
and allergy. Our data indicated that AD+ participants had up-regulated Th2 in response 
to helminth infection and AD- participants are more likely to develop a low-grade 
asymptomatic infection. We postulate that already atopic children exposed to helminths 
will clear the infection faster, and the helminth will not have time to exploit unique 
modulation of immunity through antigen-specific IgG4. In contrast, a non-atopic child 
would develop low-grade infection allowing time for the helminth to modulate its 
immune environment. Here we see how helminth infection and allergy could clash or 
coincide when it comes to immune regulatory balance in the lung.  
 
What can be gathered from this information is that the polarisation of an immune 
response, specifically in a tightly regulated area such as the lung, is not as binary as 
previously assumed. The IgE-IgG4 balance still remains on a scale; it’s the magnitude 
of infection that varies. In the case of AD+ infection, clearance happens because Th2 
activation is already high and in the case of the AD- the Th2 activation is lower, 
interestingly we do not know how the variation or effect of SP-D fits into that model. 
 
The influences of the rural-urban divide on allergic disease. In South Africa, like 
other developing countries, the prevalence of the non-communicable disease in children 
is a growing public health concern (WHO, 2010). There has been a notable increase in 
the prevalence of allergic disease, in urban areas with the rate of allergy reflecting 
‘developed’ countries [181] and rural areas have a lower prevalence of respiratory 
allergies [194].  
 
The SAFFA study showed that the urban cohort was significantly more likely to have 
signs of AD or AR, have familial history of allergic disease and increased prevalence 
of comorbid allergies. The urban rate of food allergy matches middle-income countries 
with a significantly lowered rate of food allergy in rural South African children. In our 
research, we noticed a notable rural-urban variation. First, total IgG and total IgG4 
were significantly raised in urban cohort, particularly AD- group. Second, Ascaris-
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specific IgG4 titers were significantly raised in the rural cohort. Third, rural AD- 
cohort was more likely to be positive for active infection than an urban cohort. Finally, 
in the SAFFA study, we saw that urban food allergy rates were significantly raised 
compared to the rural cohort.  
 
Other research also suggests variation in sensitisation and allergy. This is based on 
socioeconomics between children of different ethnicities, as well as children of recently 
urbanised immigrants, compared to local population	 [195]. South Africa, like many 
other developing countries, has juxtaposition between urban and rural populations and 
vulnerability to disease; when normalising for ethnic demographics, rural populations 
have different susceptibilities to disease entirely [181]. There are distinct parallels in 
the epidemiology of atopic dermatitis, asthma and allergic rhinitis. According to the 
model of allergic march, eczema (AD) precedes the development of asthma and allergic 
rhinitis (AR) [184]. 
 
Furthermore, there is a large body of evidence showing the likelihood of comorbidity 
of asthma and allergic rhinitis [196] [197]. In adult studies, 30% to 90% of participants 
with asthma also have allergic rhinitis, and these share similar pathophysiology [196]. 
The evidence from the SAFFA study, our data, and other research suggests that rural-
urban differences could be as important a factor as ethnicity and genetic determinants, 
in the development of the immune response and potentially as a knock-on for food 
allergy and other allergic diseases. 
 
This raises the question of how a rural-urban divide that influences quantitative 
outcomes must be considered whilst conducting research. How should it be considered 
and what exactly should be considered? Should it be used to normalise data using the 
urban/rural geography?	 
 
This section answers objective four, illustrating that participants with allergic disease 
have altered response to helminth infection and helminth infection alters the phenotype 
of allergic disease. 
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3.3.4 Chapter conclusion 
There is an interplay between helminth & SP-D, helminth & allergy and SP-D & 
allergy, but what about the system as a whole? We know that SP-D correlates to 
increased Ascaris IgG4 and that SP-D binds to allergens and to helminths directly [69]. 
What is unknown is how SP-D elicits an effect. SP-D increases in some allergic disease 
(according to lung proximity) and our data shows an increase during specific helminth 
infections. Our lab also showed that addition of SP-D associates with up-regulation of 
Th2 responses [69]. These results point to the ability of SP-D to alter the mechanism 
by which Th2 immunity functions in the lung and other mucosal barriers. Under normal 
conditions, SP-D’s CRD binds to helminth and allergens driving a Th2 phenotype, and 
subsequent clearance through phagocytosis or opsonisation [198]. In an allergic 
condition, SP-D competes with allergic immune responders and decreases the amount 
of available binding sites on an allergen, lowering the immune stimuli and mediating 
the allergic response. Upon binding through its CRD, SP-D is classically anti-
inflammatory but when barrier integrity is lessened and the oxidation state of the 
microenvironment changes, SP-D could have an inflammatory effect due to its 
breakdown from multimer to monomers [148]. In helminth infection, the same 
mechanism of binding to available epitopes on the helminth itself could limit immune 
stimuli, changing of course with a shift in barrier integrity.  
 
We know in murine models of allergic disease, administration of large quantities of SP-
D and rfhSP-D suppresses IgE (antigen-specific), reduces eosinophilia and causes Th-
1 cell polarisation [92]. It is larger but still comparable to SP-D leakage into serum from 
the lung of allergic asthma patients.  We did not see the same leakage and subsequent 
raised level of serum SP-D that we attribute to the different pathophysiology of atopic 
dermatitis compared to lung allergy. With Ascaris and Toxocara infection transitioning 
through the lung as part of the lifecycle, where allergic asthma causes damage to the 
alveolar epithelium, the physical size of the helminth can cause similar damage 
resulting in the leakage of SP-D. This leaked SP-D would have an effect on serum 
immunoglobulins, throwing the IgG4-IgE balance into disarray. 
This dissertation, supported by other studies, points to there being a novel association 
between SP-D and helminth-specific IgG4, related to the proximity of the helminths to 
the lung. We are also seeing an upregulation of Th2 immunity in the lung in allergic 
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participants which increases their ability to clear the helminth infection quickly. SP-D 
has an effect on the allergic disease but is not a marker of severity for atopic dermatitis. 
Finally, the rural-urban divide in South Africa plays a role in the prevalence of allergic 
disease and other undetermined health outcomes and should be considered thoroughly 
when performing research.  
There are limitations to our analysis of SP-D. The significance of a 14-sample 
comparison (Masiphumelele cohort) and 30-sample comparison (SOSALL cohort) is 
limiting; however, in this experiment, the number of IgG4 positive samples was limited. 
Future work should focus on longitudinal time points per patient and the degree of 
exposure to Ascaris infections more thoroughly assessed. This would allow specific 
conclusions to be made regarding the upregulation of serum SP-D. Finally, owing to 
the limited number of samples available and the large variability typically observed in 
patient-derived data, the statistical analysis of this study was limited to provide 
definitive conclusions. Nevertheless, the results presented provide interesting avenues 
for further research and should be explored in a larger cohort. Age must be factored in 
too, with this cohort being adult (Masiphumelele) and adolescent (SOSALL) their 
exposure to helminths and subsequent shift in SP-D is notably different.  
 
The SOSALL cohort showed low numbers of acute or actively infected children 
(previously determined IgE titer). This was expected as the tested participants are 
young and active anti-helminthic programs are being run in both rural and urban areas. 
However, previous or non-active exposure to helminths in the cohort was found to be 
very common with Ascaris lumbricoides, and Toxocara spp antigen-specific IgG4 
detected (above cut off) in over 25% of study participants and Trichuris trichuria in 
20% of participants. Despite having relatively large amounts of detectable antigen-
specific IgG4, if we compare this to total IgG4, there are fewer positive samples. The 
number of samples positive for antigen-specific IgG4 should not be more than total 
IgG4; the only explanation that we could see was an experimental error. Another 
consideration is antigenic cross-reactivity, cross-reactivity happens when an antibody 
created against one specific antigen recognises another antigen with a similar structural 
region. The helminth species that we work with are distinct in many ways but do share 
similar surface molecules that might cause cross-reactivity in experimentation. The 
antibody used to identify SP-D and the immunoglobulins are polyclonal in nature, 
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which means there is an increased chance of antigenic cross-reactivity due to the 
recognition of multiple epitopes.  
 
The use of SP-D as a biomarker is gaining traction, with other studies looking into 
similar potentials [199] [200], however, standardisation needs to be established. 
Reviewing the use of various ELISA and western blots, reported SP-D values for 
healthy control populations varied more than a hundredfold between studies [201]. On 
the one hand, the experimental methodology can have an influence on outcomes like 
the use of EDTA during blood collection results in inconsistent SP-D readouts [201], 
we should also consider that SP-D in serum in a variable between individuals due to 
genetics and environment. It is important to consider the use of SP-D as a biomarker 
but also potentially as a novel treatment for helminth infections. We know it is 
associated with helminth infections occupying the lung and has a role in binding to and 
dampening immune responses. More work should be directed towards its use as a 
treatment or host-directed therapy, moving away from anti-helminthics. Could SP-D be 
used as a novel anti-helminthic treatment for lung-based parasites?  
 
SP-D research focuses on immunomodulation, specifically its role in phagocytosis, 
optimisation and oxidative signalling. However, SP-D also interacts with various other 
cell types, including immune cells, epithelial cells, fibrocytes and smooth muscle cells. 
Another consideration is that in the majority of research the pulmonary effect of SP-D 
reviews it’s dampening of inflammation, there are also potential inflammatory effects 
of SP-D variants when SP-D does not form HMW structures. When LMW SP-D has 
generated research shows [14] that it can become inflammatory, these LMW bi-
products develop when SP-D is broken down due to a change in oxidative state in the 
pulmonary environment. LMW SP-D must be reviewed in more detail, in particular, 
focusing on what inflammatory effect LMW SP-D has on the human immune response. 
 
Helminth exposure and modulation of physiology are complex, and more investigation 
needs to be directed towards other measurable biomarkers in serum, such as antibody 
titers and cytokine responses to validate the concept of Th2 up-regulation. With our 
body of work only generated from the analysis of the serum samples, focusing in 
particular on IgG4 levels in the cohort.  
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4 Influence of SP-D and helminth antigen on cellular 
phenotypes relevant to helminth infection 
4.1 Introduction 
The relevance of surfactants in disease is multi-faceted with roles in parasitic infection 
[69], chronic non-communicable disease [199] [141] and allergy [202] [198]. Although 
the exact mechanism of interaction is still unknown, the homeostasis of surfactant, as 
well as its homeostatic abilities, appears to be critical indicators for disease and disease 
prevention. As stated previously, murine experiments within this research group have 
illustrated that SP-D enhances the innate immune defence in the protection against 
helminth infection. These results need to be translated into human studies, which was 
pursued in two directions.  
 
In the first set of experiments (Chapter 3), trends were identified surrounding SP-D and 
parasitic infection. It was showing that antigen-specific IgG4 titers associate with 
increased SP-D levels (Figure 3.4). This association could be linked to the role of SP-
D in the body but gives us a superficial indication of the cellular mechanistic. Flow 
cytometry allows phenotyping of cells based on their extracellular and intracellular 
marker repertoire. This section aimed to review the phenotypes of particular immune 
cell subtypes related to SP-D and its interaction with human helminth infections. Two 
cell types were chosen, type 2 innate lymphoid cells and myeloid lineage 
monocytes/macrophages.  
 
Studies have linked innate cell types from the myeloid lineage with resistance to 
helminth infection [9]. New research classifies monocytes into distinct human subtypes 
and functionality during infections including valuable, but undefined, roles during 
helminth infections, these cells also serve as precursors to the macrophage [67]. We 
focused on circulating monocytes due to being readily accessible through blood 
samples. Human monocytes can also be derived, ex-vivo, to form macrophages, which 
are crucial during helminth infections. Murine macrophages are known to limit type 2 
pathology by regulating cytokine production [203] [204] and are involved in tissue 
repair and fibrosis [205] [206]. Human monocyte subsets have functional variation in 
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response to helminth infection. By modelling the in vitro interaction between the filarial 
worm W. bancrofti, we see distinct categorisation into classical, non-classical and 
intermediate monocytes [207]. Macrophages and monocytes display phagocytic 
capabilities through an array of receptors and have been associated with particular 
helminth infections, both human and murine. Our cell work focused on human 
monocyte expression of CD16 and human monocyte-derived alternatively activated 
macrophage expression of CD16 and CD206.  
	
A brief overview of CD16: Monocytes and macrophages display CD16 on their 
surface, otherwise known as FcγRIII, which binds to the Fc portion of IgG. The Fcγ 
receptor group critically links humoral and innate arms of the immune response [208]. 
In humans, high-affinity binding is illustrated with IgG1 and IgG3 leading to 
phagocytosis, the release of inflammatory mediators and clearance of immune 
complexes through ADCC [208]. ADCC is a dominant mechanism in vivo that is 
involved in pathogen clearance, the destruction of cancerous cells and autoimmune 
disorders. Monocyte CD16 expression is linked to protection against schistosome 
infection, with increased CD16 associated with increased total IgG and IgG1 in healthy 
participants, but not in Schistosoma infected patients [66]. Similar to parasite-specific 
IgG and IgG1, CD16 expression in healthy individuals is associated with protection 
against schistosome infection. Notably, monocytes categorised as 'non-classically 
activated' with higher expression levels of CD16 (CD14+CD16++) have a greater 
ability to bind to Schistosome cercarial and egg E/S products [12]. These relationships 
indicate a mechanistic link between the innate and adaptive immune responses to 
helminth infection in protection against infection, whereby CD16 plays a critical role. 
 
A brief overview of CD206: CD206 is a pattern recognition receptor otherwise known 
as mannose receptor C type 1 (MRC1 or MR) present on antigen-presenting cells, 
including alternatively activated macrophages [209]	[210] [211]. Functionally, CD206 
is involved in innate immune response and active during antigen processing and 
mediating phagocytosis through the recognition of microbial carbohydrates [209]	
[210]. Macrophage CD206 recognises a variety of microorganisms, including bacteria, 
fungi, virus, and parasites (helminths specifically release substantial quantities of 
glycosylated proteins that bind to immune cells expressing MR) [211]. Many pathogens 
are coated with structures that contain mannose, and the macrophage MR acts as a 
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homeostatic receptor, by binding and clearing areas of high mannose glycoproteins 
[210]. We refer to MR as homeostatic because it is hypothesised that MR plays a crucial 
role the maintaining inflammatory stability in sensitive tissues, i.e. lung [209]. CD206 
has been used widely in the characterisation of AAMs during parasite infection [212] 
[211]; however, the exact role for CD206 is undefined in human helminth infections. 
There is a broad scope to understand how CD206 mediates and is mediated by parasitic 
infections and the presence of SP-D.  
 
As previously stated, after infection with N. brasiliensis; type 2 innate lymphoid cells 
(ILC2) are the major innate IL-13 expressing cells. In the same model, a transfer of 
wild type ILC2 cells to rag knockout mouse rescued the anti-helminthic response [61]. 
They have a role to play in type 2 immune cascades during parasitic infection. Mjosberg 
et al. were the first to describe them in humans as lineage negative CD127+ CD161+ 
expressing CRTH2 (CD294) and producing IL-13. The CRTH2 expression and IL-13 
production separate them from other innate lymphoid cells, which are classified as 
lineage negative CD127+ CD161+ [213]. To date, only a few studies have characterised 
innate lymphoid cells in humans with a parasitic disease. Boyd et al. also defined all 
ILCs as Lin-CD127+CD45+ and the expression of cKit (CD117), showing that 
exposure to microfilariae can attenuate ILC2 responses [176]. The flow cytometry 
panel and gating strategy were designed for viewing total ILC populations concurrently 
with ILC2s, which together makes up a large part of innate immune effectors to various 
diseases.  
 
Referring back to aims and objectives, here it was identified whether SP-D influences 
the magnitude of anti-nematode responses in human immune cells. The hypothesis 
is that the association between helminth exposure and SP-D relies on immune cell 
interaction, potentially involving type 2 innate lymphoid cells (ILC2s), monocytes and 
macrophages. Our objectives were as follows; (1) We set up a robust method of review 
for cellular phenotypes of ILC2's, monocytes and macrophages isolated from human 
PBMCs. (2) We then used this method to review whether SP-D and Ascaris antigen 
have an influence on these immune cells with particular focus on the effect of the 
following combinations; (A) SP-D and Ascaris individually or combined on monocyte 
CD16, (B) SP-D and Ascaris individually or combined on macrophage CD16, (C) SP-
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D and Ascaris individually or combined on macrophage CD206. It is worth noting that 
time constraints did not allow for experiments 2 (A-C) using ILC2s. 
4.2 Results 
4.2.1 Establishment of flow cytometry panel to assess phenotypes of 
monocytes/macrophages and ILC2s 
The following was the process of structuring and optimising a flow cytometry panel, 
which is a powerful tool to review cellular phenotypes at high concentration. The 
optimisation was not straightforward, particularly for cell types that are present in low 
abundance. The precision of marker overlap and antibody concentration must be high 
to robustly review these shifting cellular phenotypes. We designed our panels based 
upon existing literature and consensus on cell population size and shapes, using markers 
identified as necessary for either cell function or identification.  
4.2.1.1 Antibody titrations 
To determine the optimal volume of the antibody for detecting cell population, we 
stained cells with antibodies at a range of concentrations. This ensures that antibodies 
are used at a volume that allows for the optimal separation minimising background 
signal [178]. We surface stained cells from two individuals, as described in methods 
(see surface staining protocol), and optimal antibody concentrations were chosen based 
on the staining index. Below the workflow is illustrated, and titration calculation with 
the remaining antibodies and their calculated titration values left out for length's sake 




Figure 4.1: Representative monocyte panel titration of anti-CD3 PeCy5.5 and anti-CD16 BV421. 
(A) Represents the flow plots, where the volume of antibody added is shown on the top right-hand corner 
of each plot. A two-fold dilution series was performed, and PBMC were surface-stained and analysed 
unfixed on a flow cytometer. Cells were gated on singlet and lymphocytes. (B) The titration curve used 
to calculate MFI for the negative (-) and positive (+) population for all volumes tested. Asterisk (*) on 










Figure 4.2: Representative ILC2 panel titration of anti-lineage cocktail FITC and anti-CD294 PE. 
(A) Represents the flow plots, where the volume of antibody added is shown on the top right-hand corner 
of each plot. A two-fold dilution series was performed, and PBMC were surface-stained and analysed 
unfixed on a flow cytometer. Cells were gated on singlet and lymphocytes. (B) The titration curve used 
to calculate MFI for the negative (-) and positive (+) population for all volumes tested. Asterisk (*) on 











4.2.1.2 Building the multi-colour flow panels 
To build our monocyte and ILC2 panels we consecutively added titrated antibodies to 
develop a multi-antibody cocktail that would identify our cell populations of interest, 
this allowed us to compensate for optimal antibody separation and to troubleshoot any 
problems with interference (see methodology). 
4.2.1.3 Dump channel 
The inclusion of a dump channel allowed for the exclusion of unwanted cell 
populations, which aids in improving the quality of the data when viewing rare cell 
types. In this case, the monocyte panel has CD3 and CD19, both on Pe/Cy5 as a lineage 
cocktail (Table 2.1 methods displays cell types targeted). The ILC2 panel used a more 
complex lineage cocktail that contained CD3, CD16, CD19, CD56 and additionally 
CD11c and CD123 all on FITC (Table 2.2 in methods displays cell types and markers 
targeted). Lineage markers are used to gate out unwanted cell populations (Figure 4.3).  
4.2.1.4 Fluorescence minus one (FMO) controls and the effects of compensation 
FMOs were used to determine whether the panel of fluorochromes chosen can be 
combined. To develop a flow cytometry panel that included multiple antibodies, it is 
vital to make sure that the bleeding of one fluorochrome into another channel was 
minimised. This is achieved by performing FMOs. With regards to compensation, the 
spillover of fluorochromes into other colour channels causes false signal and irregular 
population shapes on FACS plots. We corrected for this using a mathematical matrix, 
which was applied to the fully stained samples based on single stained controls run in 





Figure 4.3: Flow cytometry gating strategies for lineage markers. This displays a comparison 
between inclusion and exclusion of lineage channel gate. (A) Monocyte panel: gating out the lineage 
cells (CD3 (T-cells) and CD19 (B-cells)) displays a large reduction in the spread of cell populations, 
increasing the accuracy of subsequent HLA-DR gate. (B) ILC2 panel: Gating out the lineage cells (CD3, 
CD14, CD16, CD19, CD56, CD11c, CD123) displays a large reduction in the spread of cell populations 




4.2.1.5 Gating strategies 
To maintain consistent results, a single gating strategy was designed based on where 
the populations appear on the flow plots. The gates were replicated per donor to ensure 
precision in the inclusion and exclusion of certain cell populations. Below are gating 
strategies decided upon and then used for ILC2s and monocytes, respectively (Figure 
4.4 and 4.5). 
	
	
Figure 4.4: Flow cytometry staining strategies for type 2 innate lymphoid cells. Flow cytometry 
gating strategies for type 2 innate lymphoid cells. This displays the full gating strategy for type 2 innate 
lymphoid cells in samples of peripheral blood mononuclear cells collected from the western province 
blood bank. (A) Size based gate (B) Single-cell gate (C) Lineage – CD45+ gate (D) CD127+ gate (E) 
































Figure 4.5: Flow cytometry gating strategies for monocytes. This displays the full gating strategy for 
monocytes in samples of peripheral blood mononuclear cells collected from the western province blood 
bank. (A) Size based gate (B) Single-cell gate (C) Lineage (CD3 & CD19) – gate (D) HLA-DR + gate 
(E) Expression of CD16 and CD14. 
4.2.1.6 Panel validation 
To establish whether we were identifying accurate cell populations, we assessed the 
literature and roughly compared published population size, shape and number to our 
own results. The spread and size of cell populations were the most important. Monocyte 
panel was validated against current human monocyte panel courtesy of Dr Heather 
Jaspan (Figure 4.7). Based on CD14 and CD16 expression monocytes are divided into 
three subsets; classical, non-classical and intermediate [66]. The ILC2 panel was 
validated against human ILC2 panel designed by Nausch et al., 2014 [177] for a cohort 
recruitment study in Zimbabwe. This new and rare cell type has proven difficult to 
identify in blood without the use of magnetic isolation kits. ILC2 populations are 
notoriously difficult to work with due to their low circulating percentage in human 
serum [214], but with the validation of the panel (Figure 4.6) and the heterogeneity 
between donors, we can be confident that this panel was a reasonably robust 


























in this case, a change in machinery to 4-laser Fortessa was required for the inclusion of 
a viability dye. The PBMC viability from a cell bank was consistently high and with a 
diminutive need for a viability marker. However, future cohort recruitment and 
variation in sample processing would require more accurate cell viability control.  
	
Figure 4.6: Comparison of type 2 innate lymphoid panel to existing literature. In order to gauge the 
accuracy of our panel, we compared our panel to existing literature from Nausch et al. 2015. The same 
markers were gated for, and population size and spread were compared. The upper row is the panel 
generated from this work, and the lower panel is Nausch et al. panel.  
	
Figure 4.7: Comparison of monocyte panel to existing literature. In order to gauge the accuracy of 
our panel, we compared our panel to existing literature from Dr Heather Jaspan, UCT. The same markers 
were gated for, and population size and spread were compared. The upper row is the panel generated 
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4.2.1.7 Using flow cytometry panels to determine the phenotypic shift in cell types 
 A preliminary phenotype comparison between the four PBMC donors (Figure 4.8) was 
created to establish whether the flow panels were working as expected, this illustrated 
the populations that will be analysed in future work with ILC2s and monocytes. ILC2 
populations are notoriously difficult to work with due to their low circulating 
percentage in human serum [214] but with the validation of the panel (Figure 4.6) and 
the heterogeneity but consistent proportionality between donors (Figure 4.8 A) this 
panel was a robust identification of small cell type. Monocyte proportionality was 
expectedly more variable (Figure 4.8 B), as monocyte proportionality between 




Figure 4.8: Donor comparison plots. Monocyte and type 2 Innate Lymphoid Cells absolute cell counts 
compared between donors. (A) Adapted Type 2 innate lymphoid cell panel utilising different 
fluorochrome labelled markers and identical gating strategy. (B) Adapted Monocyte panel utilising 
different fluorochrome labelled markers and identical gating strategy.  
4.2.2 Cellular stimulation experiments 
The cell work was conducted at the École Polytechnique Fédérale de Lausanne (EPFL) 
as part of a research internship. We focused on expanding the research previously done, 
looking at unexposed human PBMCs and their response to human SP-D, helminth 
antigen and various cytokines. The project focused on monocytes and macrophages, 































































expression and IL-13 release (no data). Human monocytes were separated using 
magnetic isolation kits based on their CD14 expression. Macrophages were also 
cultured from isolated CD14+ PBMCs (monocytes) in GM-CSF, which causes alternate 
activation. Our focus was on whether SP-D and helminth antigen cause a shift in 
expression of cellular markers on monocytes and macrophages. Stimulations were 
performed using PMA/Ionomycin. Limitation on time and reagents meant we were only 
able to perform a small number of experiments. The gating strategy used for monocyte 
and macrophage identification, respectively, is depicted below (Figure 4.9 and 4.10).  
 
	
Figure 4.9: Monocyte gating strategy and stimulation with recombinant surfactant protein D. (A) 
Monocyte gating strategy generated in Switzerland. Gating based on CD14+, single cells, and viability 
marker, CD16+ or CD206+ or IL-13.  
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Figure 4.10: Macrophage gating strategy and stimulation with recombinant surfactant protein D. 
(A) Macrophage gating strategy generated in Switzerland. Gating based on size, single cells, and viability 
marker, CD16+ or CD206+ or IL-13. 
	
4.2.3 Both SP-D and helminth antigen influence monocyte and macrophage 
phenotypes  
The cell work was re-located to the École Polytechnique Fédérale de Lausanne (EPFL) 
for a research internship. We focused on expanding the research done at UCT; looking 
at human PBMCs, specifically monocytes and macrophages, and their responses to 
human SP-D, helminth antigen. Outputs were surrounding CD16 expression, CD206 
expression and IL-13 release (no data). Limitation on time and reagents meant we were 
only able to perform a few experiments. Focussing on the data that was generated, we 
see trends surrounding both CD16 and CD206 expression. From each donor, we 
extracted the PBMC's then using magnetic isolation we extracted human monocytes 
(CD14+ cells), to either stimulate directly (PMA/ionomycin) or culture (GM-CSF) into 




4.2.3.1 SP-D has a small influence on human monocyte CD16 expression 
To establish whether SP-D had an effect on human monocytes, we assessed our chosen 
cell population's expression of CD16. We reviewed the monocyte expression of CD16, 
showing four donors under three different concentrations of SP-D (no rfhSP-D, 
20ug/ml rfhSP-D or 40ug/ml rfhSP-D) (Figure 4.11). We show all four donors in 
unstimulated conditions (Figure 4.11 A) and all four donors in stimulated conditions 
(Figure 4.11 B). Both donor AV and AZ under-stimulated or unstimulated conditions 
showed a definite decline in CD16 expression with the addition of SP-D and increased 
concentration of SP-D. The other two donors showed no conclusive trend. Inconclusive 
data from the first sets of stimulation experiments showed increased CD16 expression 
in 2 donors monocytes with SP-D (stimulated and unstimulated) and a negligible 
change in CD16 expression in 2 donors monocytes with SP-D (stimulated and 
unstimulated). No shift in negligible expression of CD206 monocytes with SP-D. Here 
we observe that SP-D has a small influence on CD16 expression of monocytes both in 
stimulated and unstimulated conditions. 
 
	
Figure 4.11: Proportion of CD16+ monocytes. Peripheral blood mononuclear cells from 4 donors treated 
with various concentrations of surfactant protein D (SP-D) either unstimulated or stimulated with 
PMA/ionomycin. Cells then analysed via flow cytometry and gated on proportions of CD14 and CD16, which 
is shown here as a percentage. (A) Shows the percentage of CD16+ monocytes left unstimulated and treated 
with variable concentrations of SP-D (B) Shows the percentage of CD16+ monocytes stimulated with 




















































































































































































































4.2.3.2 SP-D had negligible influence on human macrophage CD16 and CD206 
expression 
To establish whether SP-D had an effect on the human macrophage, we assessed our 
cell population's expression of CD16 and CD206. Macrophage expression of CD16 and 
CD206 was reviewed, with four donors in stimulated conditions under three different 
concentrations of SP-D (no rfhSP-D, 20ug/ml rfhSP-D or 40ug/ml rfhSP-D) (Figure 
4.12). Inconclusive data with variable CD16 expression, mostly negligible in 3 donors 
with massive expression seen in the 4th donor (stimulated conditions) (Figure 4.12 A). 
A variable but an increased amount of CD206 expression in donors macrophages 
(Figure 4.12 B) with similar expression levels of CD206 but upon the addition of 
Ascaris alone, Ascaris + SP-D or Ascaris + SP-D + CaCl2 the CD206 expression levels 
dropped substantially, particularly in the case of Ascaris + SP-D + CaCl2 (Figure 4.12 
B). Here we observe that SP-D has a negligible influence on human macrophage 
expression of CD16 and CD206 in both stimulated and unstimulated conditions. 
	
Figure 4.12: Proportion of CD16+ or CD206+ macrophages. Peripheral blood mononuclear cells from 
4 donors underwent magnetic isolation selecting for CD14+, which identifies circulating monocytes. 
These monocytes were then cultured with GM-CSF, which generates monocyte-derived human 
macrophages. Cells were then treated with various concentrations of surfactant protein D and calcium 
chloride and stimulated with PMA/ionomycin. Cells then run via flow cytometry and gated on 
proportions of CD16 or CD206, which is shown here as a percentage. (A) Shows the percentage of 
CD16+ macrophages stimulated treated with variable concentrations of SP-D and calcium chloride (B) 
Shows the percentage of CD206+ macrophages stimulated and treated with variable concentrations of 


















































































































































































































































































































4.2.3.3 Ascaris antigen and SP-D upregulate expression of CD16 on monocytes 
separately but combined lowered it back towards baseline  
We then went on to review the influence of live Ascaris antigen on monocyte 
phenotype. We looked at the monocyte expression of CD16 and CD206 in the presence 
of Ascaris antigen (Figure 4.13). The proportion of CD16+ monocytes and the 
influence of SP-D alone, Ascaris alone or SP-D and Ascaris in combination (Figure 
4.13 A). We see an inconclusive signal from CD206+ monocytes and the influence of 
SP-D alone, Ascaris alone or SP-D and Ascaris in combination (Figure 4.13 B). We see 
that in both donors, the addition of SP-D or antigen alone increased the expression of 
CD16. Finally, the addition of Ascaris and SP-D combined in both donors drops the 
proportion of CD16 monocytes (Figure 4.13 A). Here we observe that both Ascaris 
antigen and SP-D upregulate the expression of monocyte CD16 separately but 
combined lower its expression back towards baseline. The nature of this effect should 
be further investigated to elucidate whether the effect is through direct interaction or 
stimulation of other receptors.  
	
Figure 4.13: Proportion of CD16+ or CD206+ monocytes during exposure to Ascaris. Peripheral 
blood mononuclear cells from 2 donors stimulated with PMA/ionomycin and treated with various 
concentrations of surfactant protein D (SP-D) in the presence of live Ascaris (species) worm. Cells then 
analysed via flow cytometry and gated on proportions of CD16 or CD206, which is shown here as a 
percentage. (A) Shows the percentage of stimulated CD16+ monocytes under various conditions in vitro. 































































































































































































































4.2.3.4 Macrophage CD206 and CD16 decreased with the addition of antigen 
alone, antigen combined with SP-D, decreased further with antigen & SP-
D & CaCl2.  
Here we show macrophage expression of CD16 and CD206 with antigen (Figure 4.14), 
reviewing proportion of CD16+ macrophages with SP-D alone, Ascaris alone or SP-D 
and Ascaris (combined) (Figure 4.14 A), the proportion of CD206+ macrophages with 
SP-D alone, Ascaris alone or SP-D and Ascaris (combined) (Figure 4.14 B). Both 
donors (stimulated) with a high baseline CD16 expression, the addition of Ascaris 
antigen dropped donors CD16 to negligible levels (Figure 4.14). Addition of SP-D or 
SP-D+CaCl2 increased the CD16 expression back towards baseline (Figure 4.14). The 
macrophages from both donors had similar expression levels of CD206. Still, upon the 
addition of Ascaris alone, Ascaris + SP-D or Ascaris + SP-D + CaCl2 the CD206 
expression levels dropped substantially (Figure 4.14 B), particularly in the case of 
Ascaris + SP-D + CaCl2. Here we observe the effect of antigen, SP-D and calcium, 
which lowers the expression of macrophage CD206 and CD16.  
	
Figure 4.14: Proportion of CD16+ or CD206+ macrophages during exposure to Ascaris. Peripheral 
blood mononuclear cells from 2 donors stimulated with PMA/ionomycin and treated with various 
concentrations of surfactant protein D (SP-D) in the presence of live Ascaris (species) worm. Cells then 
run via flow cytometry and gated on proportions of CD16 or CD206, which is shown here as a 
percentage. (A) Shows the percentage of stimulated CD16+ macrophages under various conditions in 




































































































































































































































































4.3.1 The effect of SP-D and Ascaris on human monocytes and macrophage 
(CD16 expression) phenotypes 
SP-D is known to directly bind to other helminth antigens [69] through its carbohydrate 
recognition domain, with no research looking into whether Ascaris binds directly with 
SP-D, we postulated that because of surface carbohydrates present on Ascaris there 
would be direct binding. Other research confirms the helminth-monocyte trend that we 
observed in our data, with monocyte CD16 expression increased with parasite-specific 
IgG and IgG1 (schistosome infection). This is associated with protection against 
parasites in healthy adults [66]. The study mentioned above used a cohort of patients 
that have already been exposed and developed resistance to schistosome infection in 
vivo. The development of protective antibodies (Fc chain of IgG) would potentially act 
directly with monocyte CD16. Our trend showed similar increased expression of CD16 
upon exposure to live worm antigen in vitro; however since no protective antibodies 
were present, the interaction might be more complicated than simply the effect of 
protective antibodies reacting with CD16.  
 
CD16 expression on both monocytes and macrophages was influenced by the addition 
of SP-D or antigen alone and in combination. SP-D and Ascaris influenced host 
immunity through a change in human monocyte CD16 function. The individual 
addition of Ascaris or SP-D increased expression of CD16. Ascaris has a larger effect 
in upregulation than that of SP-D. Interestingly, when Ascaris and SP-D are added, the 
combined effect was downregulated close to baseline CD16 expression. We postulate 
that SP-D bound directly to Ascaris and that SP-D indirectly interacted with monocyte 
due to upregulation of CD16. In an in vivo model, CD16 upregulation would bind to a 
specific antibody that activates the process of ADCC. Ascaris alone also upregulates 
CD16 through direct interaction with the immune cell. We hypothesise that SP-D could 
indirectly influence monocyte expression of CD16 on the cell specifically, by a 
mechanism as of yet, undescribed. SP-D could also compete for Ascaris antigen-
binding sites mitigating effect on monocyte. However, the combined effect of Ascaris 
and SP-D on monocyte CD16 dampens expression back towards baseline.  
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SP-D and Ascaris influenced host immunity through a change in human monocyte-
derived macrophage CD16 function. The addition of Ascaris antigen downregulated 
both donors macrophage CD16 expression to almost negligible levels, interestingly the 
addition of SP-D or SP-D+CaCl2 upregulated the CD16 expression back towards the 
baseline, rescuing the response. Again, we postulated that SP-D binds directly to 
Ascaris. We know in an in vivo model, CD16 upregulation would bind to the specific 
antibody that activates the process of ADCC. However, unlike monocyte CD16, the 
addition of Ascaris alone downregulated CD16 in macrophages. The addition of SP-D 
or SP-D+CaCl2 seems to have begun to upregulate CD16 again; we hypothesise that 
this is either through an interaction with the macrophage itself or because SP-D binds 
directly to helminth antigen competing for binding sites. As this is a time-dependent 
process, we would need to conduct more experiments in a time-dependent manner to 
confirm this. 
 
Interestingly, we saw opposing effects of Ascaris on monocyte and macrophage 
expression of CD16. Monocyte CD16 increased in the presence of Ascaris, and 
macrophage CD16 expression decreased. In both cases, the addition of SP-D dampened 
the effect of Ascaris antigen on CD16 back towards the original baseline level of 
expression. This section illustrated that SP-D and helminth antigen had an influence 
on human CD16 expression on both monocytes and macrophages.  
4.3.2 The effect of SP-D and Ascaris on human macrophages (CD206 
expression) phenotypes 
The three prevailing cell types in the lung alveoli are alveolar type I cells, alveolar type 
II cells and alveolar macrophages. MR's abundance in the lung comes from the surface 
expression on alveolar macrophages	[215], which is how they interact with and detect 
helminth antigen. Alveolar macrophages are the first line of defence in the protection 
against not only inhaled pathogens but resident pathogens as well (i.e. lung based 
helminth infection). To avoid compromising gaseous exchange, they are unique in their 
function as a macrophage, and tightly regulated to prevent unnecessary inflammatory 
responses [216]	 [133]. Part of their unique phenotype includes greater phagocytic 
abilities and increased expression of receptors of innate immunity, like MR [217]. 
Circulating monocytes do not supply resident alveolar macrophages; instead, alveolar 
macrophages develop shortly after birth [218]. Although with macrophages that are not 
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AM's, rather human monocyte-derived macrophages, they still give us an idea of 
specific responses to stimuli. 
 
Similarly, SP-D and SP-A are released by another common cell in the lung; type 2 
alveolar cells, this is in response to signals from the epithelium via cytokines such as 
IL-33, IL-25 and TSLP. We know SP-A upregulates the surface expression of MR on 
human macrophages, this upregulation enhances phagocytosis of invading pathogens. 
It would, therefore be logical to assume that SP-D has a similar effect on the expression 
of MR in human alveolar macrophages [219]. In our research with mouse modelled 
nematode infection, SP-D has been shown to interact directly both with the antigen (via 
CRD) and alveolar macrophages following N. brasiliensis infection and to increase 
expression of AAM markers after IL-4/IL-13 treatment ex vivo [37]. We know 
pulmonary surfactants actively suppress alveolar macrophage activation during resting 
conditions [220]. Alveolar macrophages also phagocytose excessive surfactant proteins 
[218]. With SP-D functioning as a soluble PRR and MR functioning as a macrophage 
bound PRR, we see an interesting mechanism by which the balance of type 2 
inflammation may be kept in check. This is an example of SP-D mediated 
downregulation of macrophages during helminth exposure and shows the critical 
linkage between innate and adaptive arms of immunity.  
 
SP-D and Ascaris, alone or in combination cause a shift in macrophage expressing 
CD206 and potentially influences macrophage phenotype as a whole. In our findings, 
we saw human monocyte-derived macrophages expression of CD206 decreased, or is 
downregulated upon the addition of Ascaris, Ascaris+SP-D and decreased further with 
Ascaris+SP-D+CaCl2. As CD206 (MR) is a pattern recognition receptor on 
macrophages, likely, it binds directly to surface carbohydrate molecules on Ascaris. 
SP-D is known to directly bind to other helminth antigens [69] through its carbohydrate 
recognition domain, with no SP-D specific Ascaris binding research we postulate that 
because of surface carbohydrates present on Ascaris there will be direct binding. The 
amount of antigen available for binding to macrophages is decreased, which could be 
the mechanism by which CD206 decreases. This section illustrated that SP-D and 
Ascaris individually or combined have an effect on macrophage CD206. 
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An observation that came out of our data was that adding CaCl2 decreases CD206 on 
macrophages. SP-D is mediated by calcium-binding in vivo [129] and here we see the 
dampening of CD206 expression on macrophages which is enhanced by calcium.  We 
have observed that the addition of calcium further drives the SP-D mediated 
downregulation of CD206 on macrophages, which is, as of yet, an undescribed 
mechanism that warrants further investigation. 
4.3.3 Chapter conclusion 
This chapter was an exploratory analysis of certain human immune cell types and the 
specific effect of surfactant protein D and Ascaris. We see that SP-D and Ascaris had 
an effect on both CD16 and CD206. Our small amount of data may point to there being 
both direct and indirect methods by which SP-D and Ascaris have an influence on CD16 
and CD206 expression. We postulate that in the case of CD16 and CD206 on either cell 
types, there are different mechanisms at play here; direct binding, competition for 
binding sites or indirect activation through another receptor or cell. 
There are a few considerations that must be made surrounding SP-D use in vitro; in 
these experiments, we used recombinant fragment SP-D which contains only the 
carbohydrate recognition domain (Figure 1.8) and whilst this is the principal means by 
which SP-D interacts, as discussed earlier, different oxidative states in the pulmonary 
environment can generate opposing effects with the N-terminal domain leading to 
alternate macrophage polarisation [129]. Not only does the direction by which SP-D 
binds have an influence on its effect but also the structures that SP-D forms before 
interacting with the surrounding environment, SP-D's monomeric subunits can arrange 
into trimers, hexamers, dodecamers and then multiunit dodecamers that resemble a 
'fuzzy ball' (Figure 1.8). These more complex arrangements centre around the N-
terminus, hiding it and leaving multiple CRD binding points exposed for binding. 
Although trends are visible, due to time and budgetary constraints, we have limited data 
generated from these stimulations.  
 
The conclusion is also limited by the size of the sample pool that was used, which limits 
our ability to run reliable statistical analysis. We are also limited by flow cytometry and 
the background noise generated by this experimental technique, with smaller, more 
niche cells populations, it becomes difficult to discern what are truly positive results. 
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Future work should consider the addition of more samples, controls, different oxidative 
states and different calcium levels. Not only do we need to be aware of the particular 
molecular binding positions but also look at expanding the participants. Using 1-2 
donors to understand an immune mechanism that can be primed by so many external 
factors is not viable, performing the experiments on a larger cohort should be 
considered for future work.   
 
Circulating monocytes do not supply resident alveolar macrophages; instead, alveolar 
macrophages develop shortly after birth [218]. With human research, it is critical to 
turn focus to the cell types in question within their microenvironment and not just 
perform experiments on circulating cell types that are not primed in the same way as 
tissue-resident cell types. The context of interactions is vital; it is always wise to 
question these findings relate to the specific mechanisms going on in stimulation 
experiment and how this finding relates to the infection in vivo.  
 
Type 2 innate lymphoid cells also have a large role to play in response to helminth 
infection, we have already created the means by which to analyse them, so it would be 
interesting to perform similar SP-D & Ascaris exposure experiments on this rare and 
very powerful cell type that is known to interact with helminth infections.  
 
Research points to the assumption that SP-D binds to Ascaris, and it would be ideal to 
confirm that through binding assay experiments surrounding particular Ascaris antigens 
and SP-D in monomeric to multimeric forms.  
 
Helminth infection induces a regulatory phenotype in DC's which in turn through the 
activation of TLR2, SP-D also induces this phenotype [182]. Perhaps this mechanism 
is a means by which SP-D indirectly causes regulation in the lung downregulating 
immune response. The investigation of DCs and its markers could be a vital step 
forward in unravelling the network of interaction. 
 
For human monocyte experiments, expansion of the flow cytometry panel to include 
more of the Fcγ receptor family would be optimal to fully assess the influence of SP-D 
on host immunity through alteration of human monocyte function. Monocytes express 
Fcγ (CD16) as well as the inhibitory receptor, FcγRIIb (CD32)	[221]	[222], and high 
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affinity receptor for IgG, FcγR1a (CD64)	 [221] [222]. Expression levels of these 
receptors may further indicate how human monocytes alter in response to infection, 




5 Overall conclusion 
 
The type 2 immune cascade in helminth infection involves damage to the epithelial 
layers in the body leading to the release of IL-25, IL-33 and TSLP, which triggers the 
downstream activation of effector populations in an attempt to expel the helminth. In 
helminth infections involving lung colonisation, the primary cell type releasing IL-33 
and priming anti-helminthic responses are alveolar type II cells (ATII cells). Another 
major immunomodulatory protein released by ATII cells is surfactant protein D (SP-
D). Classified as a hydrophilic pulmonary collectin, SP-D plays a vital role in the 
modulation of mucosal immunity during exposure to microbes.  
Recently, data emerging from our research group at UCT (Thawer et al., under review 
PLOS Pathogens) links the specific control of mouse-modelled nematode infections 
with SP-D. The research demonstrated that infection with N. brasiliensis correlated 
with increased lung SP-D levels (Figure 1.6A) and the administration of recombinant 
SP-D protects against N. brasiliensis infection by reducing worm burden (Figure 1.6Bi) 
and drove the expansion of ILC2s and CD4+ T-cells (Figure 1.6Bii and Figure 1.6Biii). 
Therefore we hypothesised that SP-D could function as a novel anti-helminthic in 
human infections. 
We determined that, in human sera, and Ascaris lumbricoides infection alters systemic 
levels of surfactant protein D. Western blot analysis highlighted the unique association 
between SP-D and Ascaris-specific IgG4. We then went on to determine that 
association exists in a larger cohort, with it being specific to helminth species that 
transit the lung as part of their lifecycle. The cohort also contained data pertaining to 
allergic disease, in specific atopic dermatitis, we see SP-D is not an indicator for the 
severity of AD, unlike other diseases. The atopic participants also had increased levels 
of atopic sensitisation, with very low levels of active infection, we attribute this 
phenomenon to upregulated Th2 response in allergic disease, leading to faster parasite 
clearance. Our antibody data also gives insight into the role of the IgE – IgG4 balance 




Interestingly, we also saw evidence of the rural-urban divide prevalent in exposure to 
helminth infections, risk of allergy, levels of SP-D, all suggestive of geography and 
genetic background being highly determinate in health and disease outcomes. There 
seems to be a clear mechanism at play here, but an expansion on cohort size as well as 
looking at other markers in serum should be considered. Helminth exposure and 
modulation of physiology are complex; more investigation needs to be directed towards 
other measurable biomarkers in serum such as antibody titers and cytokine responses 
to validate the concept of Th2 up-regulation and the homeostatic abilities of SP-D. 
 
With the limiting nature of human sample work, this investigation progressed on to cell 
phenotyping and manipulating controlled environments to gather more information on 
surfactant protein D's immunological impact on type 2 immunity. Therefore we 
designed and optimised two antibody panels for flow cytometry to review 
monocyte/macrophage and ILC2 phenotypes in response to both helminth antigen and 
SP-D. When our research shifted to a lab in Switzerland, the second panel was in major 
use with monocytes and monocyte-derived macrophages. Human work can be fickle, 
and the purpose of this investigation was to move away from recruitment of samples 
and limited investigation through serum protein levels and on to understanding the 
mechanics of how SP-D effects the immunology of helminth infection in humans.  
 
We observed the in vitro effect of helminth function on immune cells by first seeing 
that, with CD16 expression, Ascaris upregulates it on monocytes and downregulates it 
on macrophages. The addition of SP-D rescues that effect, on both cell types, towards 
the baseline. We then reviewed the CD206 expression on macrophages exposed to 
Ascaris and saw that CD206 is downregulated, and the addition of SP-D downregulates 
it further. These findings point to the modulatory role that SP-D plays during infection 
with a parasite, through both direct and indirect binding and competition for epitopes.  
 
The cell types in use must be considered; they are not a true reflection of alveolar 
macrophages with human research it is critical to turn focus to the cell types in question 
within their microenvironment and not just run experiments on circulating cell types 
that are not primed in the same way as tissue-resident cell types. Considerations must 
also be made for the structural complexity with which SP-D binds.  
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All of this data points to expansive effects of SP-D on the immune system, with 
indirectly mediated downregulation of inflammatory responses the interplay between 
SP-D and antigen directly, specifically when that antigen is immunomodulatory. There 
are multiple avenues by which SP-D and helminths affect the immune system they 
occupy both through direct binding, competition for binding sites or indirect activation 
of another cell type. Future work should be directed towards other measurable 
biomarkers in serum, such as antibody titers and cytokine responses and expansion of 
the flow cytometry panels and including more cell types in the analysis. 
 
These findings point to the need for further investigation into the novel role of SP-D in 
the control of human helminth infections in the context of immune mechanisms, 
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